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Abstract: BACKGROUND Many patients with an exacerbation of chronic obstructive pulmonary dis-
ease (COPD) are treated with antibiotics. However, the value of antibiotics remains uncertain, as sys-
tematic reviews and clinical trials have shown conflicting results. OBJECTIVES To assess effects of
antibiotics on treatment failure as observed between seven days and one month after treatment initia-
tion (primary outcome) for management of acute COPD exacerbations, as well as their effects on other
patient-important outcomes (mortality, adverse events, length of hospital stay, time to next exacerbation).
SEARCH METHODS We searched the Cochrane Central Register of Controlled Trials (CENTRAL), in
the Cochrane Library, MEDLINE, Embase, and other electronically available databases up to 26 Septem-
ber 2018. SELECTION CRITERIA We sought to find randomised controlled trials (RCTs) including
people with acute COPD exacerbations comparing antibiotic therapy and placebo and providing follow-
up of at least seven days. DATA COLLECTION AND ANALYSIS Two review authors independently
screened references and extracted data from trial reports. We kept the three groups of outpatients, inpa-
tients, and patients admitted to the intensive care unit (ICU) separate for benefit outcomes and mortality
because we considered them to be clinically too different to be summarised as a single group. We con-
sidered outpatients to have a mild to moderate exacerbation, inpatients to have a severe exacerbation,
and ICU patients to have a very severe exacerbation. When authors of primary studies did not report
outcomes or study details, we contacted them to request missing data. We calculated pooled risk ratios
(RRs) for treatment failure, Peto odds ratios (ORs) for rare events (mortality and adverse events), and
mean differences (MDs) for continuous outcomes using random-effects models. We used GRADE to assess
the quality of the evidence. The primary outcome was treatment failure as observed between seven days
and one month after treatment initiation. MAIN RESULTS We included 19 trials with 2663 participants
(11 with outpatients, seven with inpatients, and one with ICU patients).For outpatients (with mild to
moderate exacerbations), evidence of low quality suggests that currently available antibiotics statistically
significantly reduced the risk for treatment failure between seven days and one month after treatment
initiation (RR 0.72, 95% confidence interval (CI) 0.56 to 0.94; I² = 31%; in absolute terms, reduction in
treatment failures from 295 to 212 per 1000 treated participants, 95% CI 165 to 277). Studies providing
older antibiotics not in use anymore yielded an RR of 0.69 (95% CI 0.53 to 0.90; I² = 31%). Evidence
of low quality from one trial in outpatients suggested no effects of antibiotics on mortality (Peto OR
1.27, 95% CI 0.49 to 3.30). One trial reported no effects of antibiotics on re-exacerbations between two
and six weeks after treatment initiation. Only one trial (N = 35) reported health-related quality of life
but did not show a statistically significant difference between treatment and control groups.Evidence
of moderate quality does not show that currently used antibiotics statistically significantly reduced the
risk of treatment failure among inpatients with severe exacerbations (i.e. for inpatients excluding ICU
patients) (RR 0.65, 95% CI 0.38 to 1.12; I² = 50%), but trial results remain uncertain. In turn, the effect
was statistically significant when trials included older antibiotics no longer in clinical use (RR 0.76, 95%
CI 0.58 to 1.00; I² = 39%). Evidence of moderate quality from two trials including inpatients shows no
beneficial effects of antibiotics on mortality (Peto OR 2.48, 95% CI 0.94 to 6.55). Length of hospital
stay (in days) was similar in antibiotic and placebo groups.The only trial with 93 patients admitted to
the ICU showed a large and statistically significant effect on treatment failure (RR 0.19, 95% CI 0.08 to
0.45; moderate-quality evidence; in absolute terms, reduction in treatment failures from 565 to 107 per
1000 treated participants, 95% CI 45 to 254). Results of this trial show a statistically significant effect on
mortality (Peto OR 0.21, 95% CI 0.06 to 0.72; moderate-quality evidence) and on length of hospital stay
(MD -9.60 days, 95% CI -12.84 to -6.36; low-quality evidence).Evidence of moderate quality gathered
from trials conducted in all settings shows no statistically significant effect on overall incidence of adverse
events (Peto OR 1.20, 95% CI 0.89 to 1.63; moderate-quality evidence) nor on diarrhoea (Peto OR 1.68,
95% CI 0.92 to 3.07; moderate-quality evidence). AUTHORS’ CONCLUSIONS Researchers have found
that antibiotics have some effect on inpatients and outpatients, but these effects are small, and they are
inconsistent for some outcomes (treatment failure) and absent for other outcomes (mortality, length of
hospital stay). Analyses show a strong beneficial effect of antibiotics among ICU patients. Few data
are available on the effects of antibiotics on health-related quality of life or on other patient-reported
symptoms, and data show no statistically significant increase in the risk of adverse events with antibi-
otics compared to placebo. These inconsistent effects call for research into clinical signs and biomarkers
that can help identify patients who would benefit from antibiotics, while sparing antibiotics for patients
who are unlikely to experience benefit and for whom downsides of antibiotics (side effects, costs, and
multi-resistance) should be avoided.
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A B S T R A C T
Background
Many patients with an exacerbation of chronic obstructive pulmonary disease (COPD) are treated with antibiotics. However, the value
of antibiotics remains uncertain, as systematic reviews and clinical trials have shown conflicting results.
Objectives
To assess effects of antibiotics on treatment failure as observed between seven days and one month after treatment initiation (primary
outcome) for management of acute COPD exacerbations, as well as their effects on other patient-important outcomes (mortality,
adverse events, length of hospital stay, time to next exacerbation).
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library, MEDLINE, Embase, and
other electronically available databases up to 26 September 2018.
Selection criteria
We sought to find randomised controlled trials (RCTs) including people with acute COPD exacerbations comparing antibiotic therapy
and placebo and providing follow-up of at least seven days.
Data collection and analysis
Two review authors independently screened references and extracted data from trial reports. We kept the three groups of outpatients,
inpatients, and patients admitted to the intensive care unit (ICU) separate for benefit outcomes and mortality because we considered
them to be clinically too different to be summarised as a single group.We considered outpatients to have amild tomoderate exacerbation,
inpatients to have a severe exacerbation, and ICU patients to have a very severe exacerbation. When authors of primary studies did
not report outcomes or study details, we contacted them to request missing data. We calculated pooled risk ratios (RRs) for treatment
failure, Peto odds ratios (ORs) for rare events (mortality and adverse events), and mean differences (MDs) for continuous outcomes
using random-effects models. We used GRADE to assess the quality of the evidence. The primary outcome was treatment failure as
observed between seven days and one month after treatment initiation.
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Main results
We included 19 trials with 2663 participants (11 with outpatients, seven with inpatients, and one with ICU patients).
For outpatients (with mild to moderate exacerbations), evidence of low quality suggests that currently available antibiotics statistically
significantly reduced the risk for treatment failure between seven days and one month after treatment initiation (RR 0.72, 95%
confidence interval (CI) 0.56 to 0.94; I² = 31%; in absolute terms, reduction in treatment failures from 295 to 212 per 1000 treated
participants, 95% CI 165 to 277). Studies providing older antibiotics not in use anymore yielded an RR of 0.69 (95% CI 0.53 to 0.90;
I² = 31%). Evidence of low quality from one trial in outpatients suggested no effects of antibiotics on mortality (Peto OR 1.27, 95%
CI 0.49 to 3.30). One trial reported no effects of antibiotics on re-exacerbations between two and six weeks after treatment initiation.
Only one trial (N = 35) reported health-related quality of life but did not show a statistically significant difference between treatment
and control groups.
Evidence of moderate quality does not show that currently used antibiotics statistically significantly reduced the risk of treatment failure
among inpatients with severe exacerbations (i.e. for inpatients excluding ICU patients) (RR 0.65, 95% CI 0.38 to 1.12; I² = 50%), but
trial results remain uncertain. In turn, the effect was statistically significant when trials included older antibiotics no longer in clinical
use (RR 0.76, 95% CI 0.58 to 1.00; I² = 39%). Evidence of moderate quality from two trials including inpatients shows no beneficial
effects of antibiotics on mortality (Peto OR 2.48, 95% CI 0.94 to 6.55). Length of hospital stay (in days) was similar in antibiotic and
placebo groups.
The only trial with 93 patients admitted to the ICU showed a large and statistically significant effect on treatment failure (RR 0.19,
95% CI 0.08 to 0.45; moderate-quality evidence; in absolute terms, reduction in treatment failures from 565 to 107 per 1000 treated
participants, 95% CI 45 to 254). Results of this trial show a statistically significant effect on mortality (Peto OR 0.21, 95% CI 0.06
to 0.72; moderate-quality evidence) and on length of hospital stay (MD -9.60 days, 95% CI -12.84 to -6.36; low-quality evidence).
Evidence of moderate quality gathered from trials conducted in all settings shows no statistically significant effect on overall incidence
of adverse events (Peto OR 1.20, 95% CI 0.89 to 1.63; moderate-quality evidence) nor on diarrhoea (Peto OR 1.68, 95% CI 0.92 to
3.07; moderate-quality evidence).
Authors’ conclusions
Researchers have found that antibiotics have some effect on inpatients and outpatients, but these effects are small, and they are
inconsistent for some outcomes (treatment failure) and absent for other outcomes (mortality, length of hospital stay). Analyses show a
strong beneficial effect of antibiotics among ICU patients. Few data are available on the effects of antibiotics on health-related quality
of life or on other patient-reported symptoms, and data show no statistically significant increase in the risk of adverse events with
antibiotics compared to placebo. These inconsistent effects call for research into clinical signs and biomarkers that can help identify
patients who would benefit from antibiotics, while sparing antibiotics for patients who are unlikely to experience benefit and for whom
downsides of antibiotics (side effects, costs, and multi-resistance) should be avoided.
P L A I N L A N G U A G E S U M M A R Y
Are antibiotics beneficial for flare-ups of chronic obstructive pulmonary disease?
Review question
We conducted this systematic review to find out if the benefits of taking antibiotics for flare-ups of COPD outweigh potential harms
(e.g. risks of multi-resistant bacteria for this population).
Background
Chronic obstructive pulmonary disease (COPD) is a chronic condition (most often caused by smoking or environmental exposure)
that affects the passage of air into and out of the lungs. As a consequence, patients experience shortness of breath and coughing. Flare-
ups of COPD are a hallmark of more advanced stages of the disease. Flare-ups are defined as sustained worsening of symptoms from
the patient’s usual stable state. Commonly reported symptoms include worsening breathlessness, cough, increased sputum production,
and change in sputum colour. Clinicians frequently prescribe antibiotics for flare-ups in patients with COPD, although the cause of
flare-ups is often difficult to determine (viral, bacterial, environmental).
Study characteristics
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Evidence gathered for this review is current to September 2018. We found 19 randomised studies that compared antibiotics versus
placebo in a total of 2663 COPD patients with a wide range of flare-up severity.
Key results
Analyses show that currently used antibiotics reduced treatment failures (no improvement in symptoms, despite treatment, within 7
to 28 days, depending on the study) compared with placebo in outpatients with mild to moderate flare-ups, as well as in patients
admitted to an intensive care unit for very severe flare-ups with respiratory failure. However, antibiotics did not reduce treatment failures
among hospitalised patients with severe flare-ups, although we are less certain about this result because the effect estimate also suggested
findings similar to those seen in outpatients, but the confidence interval crossed 1.0. Use of antibiotics led to reduced mortality only
in patients admitted to an intensive care unit, but not in patients with mild to moderate (outpatients) or severe (inpatients) flare-ups,
although deaths were rare in these latter groups. Antibiotics did not reduce length of hospital stay for hospitalised patients. Patients
treated with antibiotics experienced diarrhoea more often than those given placebo, but the difference was not statistically significant.
Reviewers could not compare the severity of underlying COPD across trials because trial authors inconsistently reported lung function
and other parameters.
Quality of the evidence
The quality of evidence for review outcomes was low to moderate.
Conclusion
Although trial results show that antibiotics were effective across outcomes for patients with very severe flare-ups and respiratory failure
who needed treatment in an intensive care unit, researchers report inconsistent effects in patients with mild to severe flare-ups. Future
high-quality studies should examine clinical signs or blood tests at the time of presentation that are useful for identifying patients who
can benefit from antibiotic therapy.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Outpatients: antibiotics compared to placebo for exacerbations of chronic obstructive pulmonary disease
Patient or population: exacerbat ions of COPD
Setting: outpat ients
Intervention: ant ibiot ics
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with antibiotics
Treatment
failure within 4 weeks -
current drugs only
Study populat ion RR 0.72
(0.56 to 0.94)
1191
(7 RCTs)
⊕⊕©©
LOWa,b
Antibiot ics: amoxicillin-
clavulanic
acid, trimethoprim-sul-
phamethoxazole,
oxytetracycline, amoxi-
cill in-cotrimoxazole,
doxycycline, ciprof loxa-
cin, or amoxicillin
295 per 1000 212 per 1000
(165 to 277)
All-cause mortality Study populat ion OR 1.27
(0.49 to 3.30)
301
(1 RCT)
⊕⊕©©
LOWc,d
Antibiot ics:
doxycycline
53 per 1000 66 per 1000
(27 to 156)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; COPD: chronic obstruct ive pulmonary disease; OR: odds rat io; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence.
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.4
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Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngrading for inconsistency: I² of 31% is not that high, but results of trials dif f er and are imprecise.
bFor one trial (Allegra), not all results are available.
cOnly one study exist ing; addit ional trials likely to change the est imates.
dThe 95%CIs of the RR 1.27 are very wide (95%CI 0.49 to 3.30).
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B A C K G R O U N D
Prescribing antibiotics for treatment of patients with chronic ob-
structive pulmonary disease (COPD) during acute exacerbations
(AECOPDs) has been, and continues to be, controversial (Labaki
2017). This controversy is based largely on data suggesting that
only about half of exacerbations are bacterial in origin, and other
causes include viral infections and environmental irritants (Patel
2002; Seemungal 2001; Sethi 2004). Bafadhel 2011 suggested that
most exacerbations can be categorised as bacteria-predominant,
eosinophil-predominant, virus-predominant, or pauci-inflamma-
tory, and thus may be susceptible to antibiotics or corticosteroids
or, in the future, to newly developed antiviral drugs.
Antibiotics are widely prescribed (Jones 2008; Pretto 2012). Rea-
sons for using antibiotics include the belief that anAECOPDmost
likely results from a bacterial infection and that antibiotics should
be given to ’be on the safe side’ - reflecting the perception that
antibiotics can prevent complications of an exacerbation such as
pneumonia. Most side effects of antibiotics are relatively minor,
thus the potential benefits of antibiotics often appear to outweigh
potential harms. The most important arguments against inappro-
priate use and overuse of antibiotics are the worldwide growing
problem of multi-resistance (WHO Factsheet no. 194), polyphar-
macy, and costs. Current guidelines do not recommend use of
antibiotics in general but do recommend antibiotic therapy for
moderately or severely ill patients with AECOPDs who have three
cardinal symptoms (increase in dyspnoea, sputum volume, and
sputum purulence), or who have two of the cardinal symptoms
including purulence of sputum, or who require mechanical venti-
lation (invasive or non-invasive) (GOLD 2018; NICE 2010). The
National Institute for Health and Care Excellence (NICE) recom-
mends antibiotic treatment for AECOPDs associated with a his-
tory of purulent sputum (NICE 2018). However, no high-quality
evidence currently supports these recommendations for symptom-
or risk-stratified treatment with antibiotics. In addition, health-
care providers may not always see the sputum, and descriptions
provided by the patient may be unreliable.
Description of the condition
Acute exacerbations of COPD are an important cause of mor-
bidity, mortality, hospital admission, impaired health status, re-
duced physical activity, and increased costs. AECOPD is defined
as an acute worsening of respiratory symptoms that results in addi-
tional therapy. Definitions of AECOPD may be symptom-based
or event-based. Criteria from Anthonisen 1987 are most com-
monly used to define the severity of an exacerbation based on
symptoms (dyspnoea, cough, and (purulent) sputum production).
The event-based definition refers to the setting and intensity of
treatment as prescribed by the treating physician.Mild AECOPDs
are those treated at home by the patient, most often using short-
acting bronchodilators. Moderate AECOPDs are those treated on
an outpatient basis with oral corticosteroids and/or antibiotics.
An AECOPD is severe if the patient requires inpatient treatment
with antibiotics and/or oral corticosteroids and/or additional treat-
ments (e.g. breathing support), and very severe if treatment in an
intensive care unit (ICU) is required because of acute respiratory
failure.
Description of the intervention
Antibiotics are antimicrobial drugs that inhibit the growth of bac-
teria or kill them, or both. A wide range of antibiotics are available
for use against different types and subtypes of bacteria. For treat-
ment of AECOPDs, broad-spectrum antibiotics such as amoxi-
cillin with clavulanic acid or a macrolide are commonly used as
first-line treatment, whereas more selective antibiotics are used in
cases of treatment failure of broad-spectrum antibiotics, or when
cultures guide the use of specific antibiotics (GOLD 2018; NICE
2018).
How the intervention might work
Around half of acute exacerbations of COPD are supposed to be
triggered by bacterial infection caused by pathogens that com-
monly colonise the respiratory tract, such asHaemophilus influen-
zae, Streptococcus pneumoniae, andMoraxella catarrhalis. The goal
of antibiotic treatment is to stop bacterial infection as the likely
cause of an AECOPD.
Why it is important to do this review
We conducted this systematic review of the literature to inform
patients, healthcare providers, and clinical practice guideline de-
velopers in a transparent way (to minimise bias) about the effects
of antibiotics on patient-important outcomes. This endeavour is
important because antibiotics are likely to be perceived as benefi-
cial in clinical practice by patients and healthcare providers based
on the fact that most patients recover within weeks of starting
treatment. However, only placebo-controlled trials can determine
the cause of such recovery, which might be attributed to natural
recovery from exacerbations (i.e. without antibiotics), effects of
antibiotics, or effects of other concomitant treatments such as sys-
temic corticosteroids. Knowledge about the effects of antibiotics
compared to placebo is important if one is to appreciate the re-
sults of the many randomised trials that have compared different
antibiotics. Only if antibiotics are effective at all will such head-
to-head trials provide useful information (Puhan 2008).
There is growing recognition that COPD is a very heterogeneous
disease (Garcia-Aymerich 2011), and that exacerbations are het-
erogeneous events (Bafadhel 2011). Systematic reviews have been
used to guide the development of strong recommendations for
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clinical practice, and review findings have helped researchers iden-
tify areas in which additional research is needed. In the light of
uncertainties surrounding the use of antibiotics for COPD exac-
erbations, it is hoped that the findings presented here will prove
useful.
This review is based in part on the protocol of a withdrawn
Cochrane Review on the same topic (Ram 2006), and it reflects
Cochrane standard methods.
O B J E C T I V E S
To assess effects of antibiotics on treatment failure as observed be-
tween seven days and one month after treatment initiation (pri-
mary outcome) for management of acute COPD exacerbations,
as well as their effects on other patient-important outcomes (mor-
tality, adverse events, length of hospital stay, time to next exacer-
bation).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We sought to include randomised controlled trials (RCTs) com-
paring an antibiotic in the treatment group versus placebo in the
control group. We included studies reported as full text, those
published as abstract only, and unpublished data.
Types of participants
Weplanned to include patients with acute exacerbations of COPD
(defined as worsening of a previously stable situation with symp-
toms such as increased dyspnoea, increased cough, increased spu-
tum volume, or change in sputum colour).
We considered studies eligible if more than 90% of participants
had received a clinical (physician-based) diagnosis of COPD or,
ideally, spirometrically confirmed COPD, and if participants were
over 40 years of age. For trials with physician-based diagnosis of
COPD (also chronic bronchitis in older studies), we considered
for inclusion only those in which more than 90% of participants
had a smoking history. We accepted physician-based diagnosis of
COPD because spirometry has limited value during an acute exac-
erbation of COPD, and because restricting the systematic review
to patients with spirometrically confirmed COPD would limit in-
clusion to trials in which detailed medical records, including pre-
vious spirometry, were available at the time of enrolment, or in
which patients at risk for exacerbation were enrolled in a stable
state and were randomised when they developed an exacerbation.
We excluded studies of patients with acute bronchitis, pneumonia,
asthma, or bronchiectasis.
Types of interventions
We included studies in which researchers administered oral or in-
travenous antibiotics daily for a minimum of two days. We ex-
cluded all studies that used antibiotics for prevention of exacerba-
tions, as this research was conducted to address a different ques-
tion. Whether oral corticosteroids were used additionally was not
an inclusion or exclusion criterion.
Types of outcome measures
Primary outcomes
• Treatment failure as observed between seven days and one
month after treatment initiation (no resolution or deterioration
of symptoms after trial medication of any duration, or death,
when explicitly stated, due to exacerbation or additional course
of antibiotics or another medication)
Secondary outcomes
• Treatment failure as observed between seven and 14 days
after treatment initiation
• All-cause mortality
• Duration of hospital admission (for inpatients)
• Admission to an ICU
• Re-exacerbations within ≥ two to six weeks from the
beginning of the index exacerbation (inpatient or outpatient
treatment, rates, or time to event)
• Adverse events
• Dyspnoea
• Hospital admission
• Health-related quality of life or functional status measures
• Time off work
• Time to next exacerbation
Search methods for identification of studies
Electronic searches
We have detailed in Appendix 1 search methods used in the pre-
vious version of this review. The previously published version
included searches up to September 2012. For this update, we
searched the Cochrane Airways Trials Register from September
2012 to 26 September 2018. The Cochrane Airways Trials Regis-
ter is maintained by the Information Specialist for the Group and
contains studies identified from several sources.
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• Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), in the Cochrane Library, via the
Cochrane Register of Studies (CRS).
• Weekly searches of MEDLINE Ovid SP.
• Weekly searches of Embase Ovid SP 1974.
• Monthly searches of PsycINFO Ovid SP 1967.
• Monthly searches of the Cumulative Index to Nursing and
Allied Health Literature (CINAHL) EBSCO.
• Monthly searches of Allied and Complementary Medicine
(AMED) EBSCO.
• Handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. We have
provided in Appendix 2 details of these strategies, as well as a list of
handsearched conference proceedings. See Appendix 3 for search
terms used to identify studies for this review.
We searched the following trials registries on 26 September 2018.
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov).
• World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch).
We applied no restrictions to searches based on date, type, or
language of publication.
Searching other resources
We scrutinised bibliographies of all selected RCTs and other sys-
tematic reviews for additional potential RCTs. We contacted the
authors of identified RCTs and pharmaceutical companies pro-
ducing antibiotics to ask about other published, unpublished, or
ongoing studies.
Data collection and analysis
Selection of studies
Two review authors (DV, RN) independently assessed the titles
and abstracts of all identified citations without imposing language
restrictions and coded them as “retrieve” (eligible or potentially
eligible/unclear) or “do not retrieve”. Two review authors (DV,
AF) then independently evaluated the full text of articles that one
review author deemed potentially eligible. We resolved disagree-
ments by consensus with close attention to the inclusion/exclu-
sion criteria. We excluded studies that did not fulfil all inclusion
criteria and listed their bibliographic details, along with reasons
for exclusion.
Data extraction and management
Two review authors (DV, AF) independently abstracted data,
which another review author (DV) double-checked and entered
into Review Manager 5.3 software (RevMan 2014). Another re-
view author (MP) spot-checked data and study characteristics for
accuracy against those provided in the trial report.
Assessment of risk of bias in included studies
Two review authors (DV, AF) assessed risk of bias using the do-
main-based approach described in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011).Domains included
an assessment of how the random sequence was generated, al-
location concealment was ensured, and blinding of participants
and personnel and outcome assessors was applied, and whether an
intention-to-treat analysis was used. We resolved disagreements
between review authors by discussion. In addition, we used the
GRADE approach to determine the quality of evidence using the
standard criteria risk of bias, inconsistency, indirectness, impreci-
sion, and other biases (Guyatt 2011).
We generated a ’Summary of findings table’ for the most impor-
tant outcomes (treatment failure, all-cause mortality, overall ad-
verse events, and diarrhoea) and assessed the quality of evidence
using GRADEpro software (GRADEpro GDT), and recommen-
dations provided in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).
Measures of treatment effect
We calculated pooled risk ratios (RRs) for binary events, Peto
odds ratios (ORs) for rare events, and mean differences (MDs) for
continuous outcomes.
For trials that included two groups receiving different antibiotics,
we treated treatment groups as one group if effects of the two
antibiotics did not differ in a statistically significant or clinically
important way.
Unit of analysis issues
The unit of analysis was the participant.
Dealing with missing data
When necessary, we contacted study authors to obtain further
information about their trials.
Assessment of heterogeneity
We kept the three groups of outpatients, inpatients, and patients
admitted to the ICU separate for most analyses except for adverse
events, because we considered these to be clinically too different
to be summarised in a single group. We considered outpatients to
have a mild to moderate exacerbation, inpatients to have a severe
exacerbation, and ICU patients to have a very severe exacerbation
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(event-based definitions of severity of exacerbations). Within the
analysis of outpatients and inpatients, we used the heterogeneity
Chi² statistic to assess statistical heterogeneity and expressed this
by using the I² statistic.
Assessment of reporting biases
For trials published after 1990, we tried to find trial registration
information and assessed whether researchers had reported all out-
comes specified there.
Data synthesis
We used fixed-effect models (or random-effects models if we ob-
served statistical heterogeneity with I² > 30%) to calculateMDs for
continuous outcomes or inverse-variance weighted pooled RRs.
For rare events and trials with treatment groups of similar size,
we used Peto’s method to pool ORs. We calculated as an absolute
measure of effect the number of events avoided or the number of
excess events reported per 1000 participants treated with antibi-
otics compared to participants given placebo.
Subgroup analysis and investigation of heterogeneity
As explained in Assessment of heterogeneity, we kept markers of
the severity of exacerbation for outpatients, inpatients, and pa-
tients admitted to the ICU separate for all benefit outcomes.
Sensitivity analysis
In performing sensitivity analysis, we restricted analyses to trials
that evaluated antibiotics in current use (e.g. amoxicillin-clavu-
lanic acid, trimethoprim/sulphamethoxazole, doxycycline, peni-
cillin, fluoroquinolones), thus excluding antibiotics rarely used for
this indication or no longer used because of serious side effects
(e.g. oxytetracycline, chloramphenicol).
R E S U L T S
Description of studies
Results of the search
Searches to 2006
An electronic search of the former non-Cochrane review con-
ducted by this author team yielded 765 references (Puhan 2007).
After assessing references on the basis of title and abstract, two
review authors independently scanned the full text of 35 stud-
ies discovered during the electronic search and an additional 30
studies identified through handsearching. Four studies were ongo-
ing trials (Brusse-Keizer 2009; Fartoukh 2004; NCT00170222;
NCT00255983). We included 13 studies (Allegra 1991; Alonso
Martinez 1992; Anthonisen 1987; Berry 1960; Elmes 1957; Fear
1962; Jørgensen 1992; Manresa 1987; Nouira 2001; Petersen
1967; Pines 1968; Pines 1972; Sachs 1995).
Searches from 2005 to 2012
We identified 226 citations via the update search (2005 to 2012) of
electronic databases. We retrieved 25 full texts and handsearched
nine protocols on www.clinicaltrials.gov. From this search, we
identified two eligible trials (Daniels 2010; Llor 2012); we iden-
tified one additional trial through handsearching (Brusse-Keizer
2009).
Searches from 2012 to 2018
We identified 244 citations during the updated search (2012
to 2018) of electronic databases. We retrieved seven full texts.
From this search, we identified three eligible trials (Hassan 2015;
van Velzen 2017; Wang 2016), as well as three ongoing studies
(NCT01091493; NCT01892488; NCT03262142) (see Figure
1).
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Figure 1. Study flow diagram.
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Included studies
We included 19 studies enrolling 2663 participants. Of these 19
studies, 11 included outpatients (Allegra 1991; Anthonisen 1987;
Berry 1960; Brusse-Keizer 2009; Elmes 1957; Fear 1962; Hassan
2015; Jørgensen 1992; Llor 2012; Sachs 1995; van Velzen 2017),
seven included patients admitted to a hospital (Alonso Martinez
1992; Daniels 2010; Manresa 1987; Petersen 1967; Pines 1968;
Pines 1972; Wang 2016), and one included patients admitted to
a medical ICU (Nouira 2001). These studies, on average, were
of small sample size with a range from 19 to 310 participants.
We could not compare severity of underlying COPD across trials
because trial authors inconsistently reported lung function and
other parameters.
We identified 15 trials as full reports in English language journals;
one trial was published in Spanish (Alonso Martinez 1992), one
was published in Italian (Allegra 1991), and one was reported as
a clinical letter to a major journal (Manresa 1987). One trial pro-
vided only analyses on adverse effects because it reported only on
treatment failure within five days of treatment initiation (Allegra
1991). We attempted to retrieve the data on treatment failure
within two weeks, which had been assessed but were not reported
(personal communication with Dr. Blasi, March 2006), but these
data were not made available to us. We have provided further de-
tails of included studies in the Characteristics of included studies
table, and a summary of interventions across studies in Table 1.
Excluded studies
We excluded 84 trials with reasons (Characteristics of excluded
studies). We most often excluded trials because they com-
pared different types of antibiotics against each other and in-
cluded no placebo arm. We identified three studies as ongoing
(NCT01091493; NCT01892488; NCT03262142).
Risk of bias in included studies
Overall we found that studies had low to moderate risk of bias (see
Figure 2 and Figure 3). Thirteen of the 19 studies (70%) correctly
performed and reported random sequence generation, blinding of
participants and personnel, and intention-to-treat analysis. How-
ever, information on blinding, completeness of outcome data, and
selective reporting was limited.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Fifteen of the 19 trials (80%) correctly performed and reported
random sequence generation. Twelve of the 19 studies (60%) cor-
rectly performed and reported allocation concealment. We judged
the remainder to be at unclear risk.
Blinding
Eight of the 19 studies (55) performed and reported blinding
of outcome assessment. We considered one study to be at high
risk and the remainder at unclear risk. Fifteen of the 19 studies
(80%) correctly performed and reported blinding of participants
and personnel.
Incomplete outcome data
We detected incomplete outcome data in three (< 20%) studies.
None of the included studies described completeness of outcome
data.
Selective reporting
For all studies, except one, it is not clear whether study authors
reported all outcomes. We know that Allegra 1991 did not report
all measured outcomes.
Other potential sources of bias
We did not identify any other potential sources of bias in the
included studies.
Effects of interventions
See: Summary of findings for the main comparison Antibiotics
compared to placebo for exacerbations of chronic obstructive
pulmonary disease: outpatients; Summary of findings 2
Antibiotics compared to placebo for exacerbations of chronic
obstructive pulmonary disease: inpatients; Summary of findings
3 Antibiotics compared to placebo overall for exacerbations of
chronic obstructive pulmonary disease; adverse events
Primary outcome: treatment failure between seven
days and one month after treatment initiation
The follow-up period for these studies to assess treatment failure
ranged from eight to 28 days. In some studies, treatment failure
outcomes were patient reported (Anthonisen 1987; Berry 1960;
Brusse-Keizer 2009; Daniels 2010; Elmes 1957; Jørgensen 1992;
Sachs 1995; van Velzen 2017; Wang 2016), and in two trials,
treatment failure outcomes were provider reported (Llor 2012;
Pines 1968), as defined by an additional course of antibiotics (
Alonso Martinez 1992; Pines 1972; van Velzen 2017), or by a
combined endpoint of additional antibiotics and death (Nouira
2001).
Outpatients
For outpatients (nine trials; 1332 participants), antibiotics sta-
tistically significantly reduced the risk for treatment failure (risk
ratio (RR) 0.69, 95% confidence interval (CI) 0.53 to 0.90; I²
= 31%; Analysis 1.1). When we restricted analysis to the seven
trials administering currently used drugs (amoxicillin-clavulanic
acid, trimethoprim/sulphamethoxazole, doxycycline, penicillin),
evidence of low quality suggested a similar effect (RR 0.72, 95%
CI 0.56 to 0.94; I² = 31%; Analysis 1.2; Figure 4), with 83 treat-
ment failures avoided per 1000 treated participants (95% CI 18
to 130). See Summary of findings for the main comparison.
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Figure 4. Forest plot of comparison: 1 Antibiotics versus placebo. Outpatients, outcome: 1.2 Treatment
failure within 4 weeks - current drugs only.
Inpatients
For inpatients (five trials; 803 participants), antibiotics had a sta-
tistically significant effect (RR 0.76, 95% CI 0.58 to 1.00; I²
= 39%; Analysis 2.1). When we restricted analysis to the four
studies that assessed currently used drugs (amoxicillin-clavulanic
acid, trimethoprim/sulphamethoxazole, doxycycline, penicillin),
we noted that evidence of moderate quality showed a similar effect
size with an effect that was not statistically significant (RR 0.65,
95% CI 0.38 to 1.12; I² = 50%; Analysis 2.2; Figure 5). For ICU
patients, one trial with 93 participants given antibiotics showed
a statistically significant effect (RR 0.19, 95% CI 0.08 to 0.45;
moderate-quality evidence; Analysis 2.1), with 458 treatment fail-
ures avoided per 1000 treated participants (95% CI 311 to 520).
See Summary of findings 2.
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Figure 5. Forest plot of comparison: 2 Antibiotics versus placebo. Inpatients, outcome: 2.2 Treatment
failure within 4 weeks - current drugs only.
Secondary outcomes
Treatment failure as observed between seven and 14 days
after treatment initiation
Included trials did not report this outcome.
All-cause mortality (current drugs only)
Four trials - two inpatient trials (Daniels 2010; Wang 2016), one
ICU trial (Nouira 2001), and one outpatient trial (van Velzen
2017) - reported mortality. Researchers reported no statistically
significant effects of antibiotics on mortality for inpatients (Peto
OR 2.48, 95% CI 0.94 to 6.55; moderate-quality evidence;
Analysis 2.3; Figure 6), nor for outpatients (Peto OR 1.27, 95%
CI 0.49 to 3.30; low-quality evidence; Analysis 1.3; Summary of
findings for the main comparison), but they showed a statisti-
cally significant effect among ICU patients favouring antibiotics
(Peto OR 0.21, 95% CI 0.06 to 0.72; moderate-quality evidence;
Analysis 2.3), with 171 deaths avoided per 1000 treated partici-
pants (95% CI 61 to 204; Summary of findings 2).
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Figure 6. Forest plot of comparison: 3 Antibiotics vs placebo overall, outcome: 3.1 Adverse events.
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Duration of hospital admission (for inpatients)
Four trials including 393 participants reported length of hospi-
tal stay (measured in days). Pooled results show no clear differ-
ences between antibiotics and placebo (mean difference (MD) -
1.91, 95% CI -5.48 to 1.66; Analysis 2.4; Figure 7). Considered
separately, the three inpatient trials favoured neither antibiotics
nor placebo (Alonso Martinez 1992; Manresa 1987; Wang 2016),
whereas the fourth trial, an ICU trial, clearly favoured antibiotics
(Nouira 2001).
Figure 7. Forest plot of comparison: 2 Antibiotics versus placebo. Inpatients, outcome: 2.4 Duration of
hospital stay (days).
Admission to an intensive care unit (ICU)
Included studies did not report this outcome.
Re-exacerbations within ≥ two to six weeks from beginning
of index exacerbation (inpatient or outpatient treatment,
rates, or time to event)
One outpatient trial with 35 participants reported the number of
participants with re-exacerbations within two to six weeks (Brusse-
Keizer 2009). Data show two re-exacerbations in the antibiotics
group versus one in the placebo group (RR 1.89, 95% CI 0.19 to
18.97; Analysis 1.4).
One inpatient trial with 194 participants reported the number
of participants with re-exacerbations (Wang 2016). Trial authors
reported 17 re-exacerbations in the antibiotics group versus 11 in
the placebo group (RR 1.56, 95% CI 0.77 to 3.16; Analysis 2.5).
Adverse events
Pooled analysis included only trials that evaluated currently used
antibiotics in both inpatients and outpatients. Five studies with
1099 participants provided data on the numbers of participants
experiencing diarrhoea (Allegra 1991; Hassan 2015; Jørgensen
1992;Nouira 2001; vanVelzen2017). Evidence ofmoderate qual-
ity shows that participants treated with antibiotics had diarrhoea
more frequently than those given placebo, but the difference did
not reach statistical significance (Peto OR 1.68, 95% CI 0.92 to
3.07; I² = 0%; moderate-quality evidence; Analysis 3.1; Figure 6).
See Summary of findings 3.
Six studies with 1544 participants provided data on the overall
incidence of adverse events in study groups (Allegra 1991; Daniels
2010; Jørgensen 1992; Llor 2012;Nouira 2001; vanVelzen2017).
Participants treated with antibiotics had more frequent adverse
events, but differences did not reach statistical significance (Peto
OR 1.20, 95% CI 0.89 to 1.63; I² = 7%; moderate-quality evi-
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dence). We have shown results for other adverse events in Figure
6.
Dyspnoea
Two studies with 300 participants reported dyspnoea at the end of
the study period (Brusse-Keizer 2009; Daniels 2010). Trial results
show no significant differences in dyspnoea between antibiotics
and placebo in either trial (outpatients: MD 0.00, 95% CI -0.97
to 0.97; Analysis 1.5; inpatients: MD -0.60, 95% CI -1.27 to
0.07; Analysis 2.6).
Hospital admission
Included studies did not report this outcome.
Health-related quality of life or functional status measures
One outpatient trial with 35 participants reported health-related
quality of life and showed no statistically significant differences
between treatment and control groups (MD 0.00, 95% CI -1.79
to 1.79; Analysis 1.6) (Brusse-Keizer 2009).
Time off work
Elmes1957, the oldest trial, reported days off work for outpatients.
The antibiotics group had statistically significantly fewer days off
work compared with the placebo group (MD -5.18, 95% CI -
6.08 to -4.28; Analysis 1.7).
Time to next exacerbation
Two outpatient trials assessed effects of antibiotics over the long
term, measured as time to next exacerbation within one year (Llor
2012; n = 310) and within two years (van Velzen 2017; n = 301).
Llor 2012 found that themedian time to the next exacerbationwas
significantly longer in the antibiotics group (233 days; interquar-
tile ratio (IQR) 110 to 365 days) than in the control group (160
days; IQR 66 to 365 days; Kaplan-Meier survival analysis, P =
0.015). In contrast, median time to the next exacerbation did not
differ between groups in van Velzen 2017, with 148 days (IQR 95
to 200) reported for the treatment group versus 161 days (IQR
118 to 211) for the control group.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Inpatients: antibiotics compared to placebo for exacerbations of chronic obstructive pulmonary disease
Patient or population: exacerbat ions of COPD
Setting: inpat ients and ICU
Intervention: ant ibiot ics
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with antibiotics
Treatment failure
within 4 weeks - current
drugs only - inpat ient
Study populat ion RR 0.65
(0.38 to 1.12)
576
(4 RCTs)
⊕⊕⊕©
MODERATEa
Antibiot ics: amoxicillin-
clavulanic
acid, trimethoprim/ sul-
phamethoxazole, doxy-
cycline, tetracycline hy-
drochloride, chloram-
pheni-
col, penicill in, strepto-
mycin, piperacillin-sul-
bactam, cef tazidime, or
levof loxacin
314 per 1000 204 per 1000
(119 to 352)
Treatment failure
within 4 weeks - drugs
not current ly used - ICU
Study populat ion RR 0.19
(0.08 to 0.45)
93
(1 RCT)
⊕⊕⊕©
MODERATEb
Antibiot ics: of loxacin
565 per 1000 107 per 1000
(45 to 254)
Durat ion of hospital
stay (days) - inpat ients
Range of durat ion of
hospital stay (days)
was f rom 8.1 to 12.3
days
MD 0.09 (-0.79 lower to
0.96 higher)
- 300
(3 RCTs)
⊕⊕⊕⊕
HIGH
Antibiot ics:
piperacillin-sulbac-
tam, cef tazidime, lev-
of loxacin, amoxicillin-
clavulanic
acid, trimethoprim/ sul-
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phamethoxazole, or ce-
faclor
Durat ion of hospital
stay (days) - ICU pa-
t ients
Mean durat ion of hospi-
tal stay (days) was 24.
5 days
MD -9.60 (-12.84 lower
to -6.36 lower)
- 94
(1 RCT)
⊕⊕⊕©
MODERATEb
Antibiot ics: of loxacin
All-cause mortality - in-
pat ients
Study populat ion OR 2.48
(0.94 to 6.55)
214
(2 RCTs)
⊕⊕©©
MODERATEc
Antibiot ics: tetra-
cycline hydrochloride,
chloramphenicol, peni-
cill in, streptomycin,
chloramphenicol, doxy-
cycline, piperacillin-sul-
bactam, cef tazidime, or
levof loxacin
31 per 1000 41 per 1000
(18 to 90)
All-cause mortality - ICU
patients
Study populat ion OR 0.21
(0.06 to 0.72)
93
(1 RCT)
⊕⊕⊕©
MODERATEb
Antibiot ics: of loxacin
217 per 1000 45 per 1000
(13 to 152)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; ICU: intensive care unit ; COPD: chronic obstruct ive pulmonary disease; MD: mean dif ference; OR: odds rat io; RCT: randomised controlled trial; RR: risk
rat io
GRADE Working Group grades of evidence.
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngrading for imprecision: the upper lim it of the 95%CI overlaps 1.0.
bOnly one study exist ing; the ef fect est imate may be substant ially dif f erent with addit ional trials.
cDowngrading for imprecision: wide 95% CI of the pooled est imate that precludes any conclusion about the ef fects of
ant ibiot ics on mortality in inpat ients.
2
0
A
n
tib
io
tic
s
fo
r
e
x
a
c
e
rb
a
tio
n
s
o
f
c
h
ro
n
ic
o
b
stru
c
tiv
e
p
u
lm
o
n
a
r
y
d
ise
a
se
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Antibiotics compared to placebo overall for exacerbations of chronic obstructive pulmonary disease
Patient or population: exacerbat ions of COPD
Setting: outpat ients and inpat ients
Intervention: ant ibiot ics
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with antibiotics
Adverse events - diar-
rhoea
Study populat ion OR 1.68
(0.92 to 3.07)
1099
(5 RCTs)
⊕⊕⊕©
MODERATEa
Antibiot ics: amoxicillin-
clavulanic acid, amoxi-
cill in, of loxacin,
piperacillin-sulbac-
tam, cef tazidime,or lev-
of loxacin-doxycycline
31 per 1000 52 per 1000
(29 to 90)
Adverse events - overall
(any adverse events not
specif ied)
Study populat ion OR 1.20
(0.89 to 1.63)
1544
(6 RCTs)
⊕⊕⊕©
MODERATEa
Antibiot ics: amoxicillin-
clavulanic acid, doxy-
cycline, amoxicillin, or
of loxacin
129 per 1000 151 per 1000
(116 to 194)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; COPD: chronic obstruct ive pulmonary disease; OR: odds rat io; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence.
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngrading for imprecision: the lower lim it of the 95%CI overlaps 1.0.2
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D I S C U S S I O N
Summary of main results
Meta-analyses show that antibiotics for acute exacerbations of
chronic obstructive pulmonary disease (AECOPDs) reduced treat-
ment failure in a statistically significant way for patients with mild
to moderate AECOPDs (outpatients) and for those with very se-
vere AECOPDs (admitted to the intensive care unit (ICU); only
one trial). Trial results show a similar magnitude of effect in pa-
tients with severe AECOPDs (inpatients), but these findings were
more uncertain and the confidence interval revealed no differences
between antibiotics and placebo. Researchers reported a statisti-
cally significant reduction in the risk of mortality among ICU pa-
tients with the use of antibiotics (only one trial available), but not
for inpatients and not for outpatients. Trial reports show that hos-
pital stay was not significantly reduced by antibiotics, except for
ICU patients (only one available trial). Review authors found few
data on the effects of antibiotics on health-related quality of life or
on other patient-reported symptoms such as dyspnoea, and noted
no statistically significant increase in the risk of adverse events with
antibiotics compared to placebo.
Overall completeness and applicability of
evidence
Review authors could not study the clinical severity of underly-
ing chronic obstructive pulmonary disease (COPD) as a potential
source of heterogeneity. Trials with information on COPD sever-
ity are rare, as lung function tests are difficult to perform during
exacerbations, and lung function results from the pre-exacerba-
tion period are not always available. Also, definitions and classifi-
cations of COPD have changed over the years, so we could extract
from the included studies no uniform classifications of COPD.
Nevertheless, the results of this review appear to be applicable to
patients with moderate to severe COPD, who typically experience
exacerbations.
Trials used no common definitions for severity of exacerbation.
Review authors noted uncertainty about the thresholds of admit-
ting patients to hospital, and about whether this concern was
comparable among trials. Stratification according to the setting in
which patients were treated represents only an approximation of
the severity of AECOPD, although COPD researchers commonly
use such an event-based definition (Rodriguez-Roisin 2000). Our
finding for beneficial effects of antibiotics for patients with very se-
vere AECOPD is to some extent consistent with that described in
theAnthonisen 1987 trial, which reported benefit for patientswith
the most severe exacerbations but not for those with mild to mod-
erate exacerbations. Results of meta-analyses for treatment fail-
ure in outpatients and inpatients (non-ICU patients) were some-
what inconsistent and may indicate that our rather conservative
approach of keeping outpatients and inpatients separate was not
necessary, and that there are other determinants of hospital admis-
sion besides the severity of an exacerbation.
Only two small trials presented patient-important outcomes such
as health-related quality of life and days off work, which are heav-
ily influenced by exacerbations and are among the main targets of
COPD treatments. Given the rather small and statistically non-
significant increase in side effects, it could be argued that treat-
ing outpatients with antibiotics is not problematic, in that some
patients may still benefit. However, this disregards the consistent
and growing problem of resistance against antibiotics and the need
to decrease utilisation of unnecessary antibiotics (WHO Factsheet
no. 194).
Overall, antibiotics provide a strong beneficial effect for ICU pa-
tients. They provide some effects for inpatients and for outpa-
tients, but these effects are small and inconsistent for some out-
comes (treatment failure) and absent for other outcomes (mor-
tality, length of hospital stay). It should be noted that the study
including ICU patients was conducted approximately 20 years
ago, and advances in the care of people admitted to the ICU have
been made since that time. Therefore, these results should be in-
terpreted and applied with caution.
Quality of the evidence
We restricted our systematic review to randomised controlled tri-
als (RCTs) and identified 19 placebo-controlled RCTs with 2663
participants. The two most common reasons for downgrading the
quality of the evidence were heterogeneity and imprecision. Sta-
tistical heterogeneity within outcomes is consistent with the in-
consistent results reported across outcomes for outpatients and
inpatients. Overall, we rated the quality of evidence as high for
hospital stay for inpatients; for six outcomes, we rated quality as
moderate (treatment failures in inpatients and ICU patients, mor-
tality in ICU patients and inpatients, diarrhoea, and any adverse
events), and for three outcomes, we rated the quality of evidence
as low (treatment failure in outpatients, mortality in outpatients
and inpatients).
Potential biases in the review process
Although meta-analyses commonly include treatment failure, it
is a limitation of this review that definitions of treatment failure
differed across trials. It is difficult to standardise the definition of
treatment failure because it may include patient-reported symp-
toms and clinical signs as well as results from laboratory testing or
imaging. However, we do not have reason to believe that different
definitions of treatment failure caused heterogeneity in our meta-
analyses. Also, we could not assess the influence of factors such as
season, severity of underlying COPD, comorbidities, or concur-
rent use of medications such as systemic corticosteroids or bron-
chodilators, as researchers reported these details inconsistently and
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to a limited extent. Although these factors should not affect the
validity of trial results (balanced between groups), it would be in-
teresting to analyse whether the chance to find an effect of an-
tibiotics depends on concurrent medications that are known to
improve patients’ health status during an AECOPD (e.g. systemic
corticosteroids).
A limitation of the present systematic review is publication bias,
which is a potential threat to any systematic review. Studies demon-
strating a positive effect for antibiotics may be more likely to be
published than those showing a negative effect. To minimise ef-
fects of missing studies, we used extensive trial search criteria with
no language restrictions and made every effort to detect unpub-
lished and ongoing studies, and we contacted the authors of our
included trials, some of whom provided additional information
about their data.
Agreements and disagreements with other
studies or reviews
Our systematic review is still largely in agreement with former
versions of this review (Puhan 2007; Vollenweider 2012), and our
findings have not changed substantially with the addition of three
new trials (Hassan 2015; van Velzen 2017; Wang 2016). Evidence
still favours the use of antibiotics in patients with very severe exac-
erbations admitted to the ICU and remains inconclusive for hos-
pitalised patients with severe exacerbations and outpatients with
mild to moderately severe exacerbations. Also, the evidence con-
cerning patient-important outcomes such as health-related quality
of life has not become stronger.
Results presented in this review are substantially less clear than
those described in the former and withdrawn Cochrane Review on
this topic (Ram 2006); this is due to the availability of more trials
and some differences in how the reviews were conducted. The
former Cochrane Review used several different outcomes - such
as peak flow, lung function, sputum purulence, and blood gases
- that we believe are not patient-important outcomes to estimate
the value of antibiotics for management of AECOPD. Also, the
former review included Elmes 1965 - a study that was not an RCT
- and excluded Berry 1960 - a study that actually was an RCT. In
addition, we were able to obtain COPD-specific data from one
RCT(Sachs 1995), which reported results for both asthmapatients
and COPD patients. Our results for mortality among inpatients
differ from those of the former Cochrane Review because that
review included the Elmes trial and did not keep ICU patients and
inpatients separate (Elmes 1965).
One systematic review - Saint 1995 - combined results from dif-
ferent outcomes in a meta-analysis. Nevertheless, review authors
concluded that an overall combined standardised mean effect size
estimate of 0.22 (95% confidence interval (CI) 0.1 to 0.34) in-
dicated a small but statistically significant effect favouring antibi-
otics over placebo. We suggest that combining different outcomes
and using standardised effect sizes is an inappropriate way to pool
results.
Several systematic reviews and (network) meta-analyses have ex-
amined the topic of antibiotics and AECOPD, but they did not
focus on the comparison of antibiotics versus placebo for treat-
ment of AECOPD, nor did they focus on comparisons of differ-
ent antibiotics (Zhang 2017), use of prophylactic antibiotics to
minimise the risk of AECOPD (Donath 2013; Herath 2013), or
use of biomarkers such as procalcitonin to guide treatment with
antibiotics (Lin 2018).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
With the exception of patients with very severe AECOPD, who
require treatment on an ICU and derive benefit from antibiotics,
uncertainty continues as to whether antibiotics reduce the risk
of treatment failure, mortality, and re-exacerbations, or improve
health-related quality of life, among COPD patients with AE-
COPD who can be treated on an outpatient basis or an inpatient
basis. Current data are not conclusive enough to show whether
antibiotics should generally be used, because results among out-
patients and inpatients are heterogeneous and are associated with
some risk of bias, and because evidence on patient-important out-
comes such as health-related quality of life is not available. This
Cochrane Review provides guideline developers with an evidence
base, but we stress that additional factors such as patient pref-
erences, resistance of bacteria to antibiotics, and cost are impor-
tant to consider when recommendations or treatment decisions
are made.
Implications for research
For the large majority of COPD patients who are treated on an
outpatient or inpatient basis because of mild to moderate exacer-
bations, additional placebo-controlled trials could determine the
effectiveness of antibiotics for short- and long-term outcomes and
for patient-important outcomes such as health-related quality of
life. It is challenging to recruit outpatients for placebo-controlled
trials because of widespread beliefs about the positive effects of
antibiotics. But as our review suggests, the evidence for benefit in
an outpatient or inpatient setting is not conclusive, meaning that
placebo-controlled RCTs may still be justified.
Conflicting evidence stimulates discussion about (bio-)markers
that could predict a bacterial infection and assist in selection of
patients who might benefit from antibiotic treatment and identi-
fication of those who are unlikely to benefit. Sputum purulence is
one of the most frequently discussed indicators that can be used
to guide antibiotic therapy. It is noteworthy that no adequately
powered RCTs have assessed effectmodification by the presence or
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absence of purulent sputum. Indirect evidence on effect modifica-
tion is available from the trials included in this systematic review.
Four trials included patients with purulent sputumonly or positive
gram stain (Brusse-Keizer 2009; Elmes 1957; Pines 1968; Pines
1972), but trial authors provided few details on how purulent
sputum was defined and measured. Of these four trials, only one
showed a statistically significant effect on treatment failure (Pines
1968), and only the most recent trial reported no effects on any
reported outcomes (Brusse-Keizer 2009). Also, the trials included
in this review have provided no indication that their results differ
from those reported by trials that did not restrict the study popu-
lation to patients with purulent sputum. Biomarkers may also be
promising as a guide to antibiotic treatment for COPD exacerba-
tions. C-reactive protein (CRP) or B-type natriuretic peptide may
be useful because both are relatively cheap and are easily available
in inpatient and outpatient settings (Daniels 2010b; Llor 2012).
Trials exploring additional candidates for guiding antibiotic treat-
ment have shown an antibiotic-sparing effect when the decision to
use antibiotics is guided by procalcitonin (Mathioudakis 2017).
Different types of studies can be done to determine the utility
of clinical signs and biomarkers in guiding antibiotic therapy for
COPD exacerbations. Additional placebo-controlled trials could
assess whether the effects of antibiotics (vs placebo) are different
in patients with (or without) purulent sputum, or with different
levels of a biomarker. Such trials would require relatively large
sample sizes to formally assess subgroup effects (effect modifica-
tion). Alternatively, researchers could undertake more pragmatic
trials, in which physicians are randomised to using or not using
a clinical sign or biomarker to guide the prescription of antibi-
otics. Such trials typically would be non-inferiority trials, which
aim to show that clinical benefit is not worse when a clinical sign
or biomarker is used but that adverse effects, cost, and bacterial
resistance could be limited by diminished use of antibiotics. One
Cochrane Review showed that procalcitonin guidance was not as-
sociated with increased mortality nor treatment failure in patients
with acute respiratory infection but significantly reduced overall
antibiotic use (Schuetz 2012). In addition, new developments in
subgroup analyses based on advanced statistical methods may help
to generate hypotheses by which patients may benefit from an-
tibiotics (Seibold 2016). Finally, observational studies may be un-
dertaken to look into the potential of clinical signs or biomarkers
for predicting outcomes of patients with COPD exacerbations.
Such studies could assess the independent predictive properties
of clinical signs or biomarkers, or could compare outcomes with
antibiotic treatment versus outcomes with no antibiotic treatment
in patients with or without a clinical sign or certain biomarker lev-
els, while adequately adjusting for selection mechanisms and con-
founding. Such observational studies appear more feasible than
additional placebo-controlledRCTs, but they often aremore likely
to be hypothesis-generating than to provide high-quality evidence
as a basis for treatment recommendations.
It would be important to gather additional high-quality evidence
on the long-term effects (re-exacerbations, health-related quality of
life, and mortality) of antibiotics for COPD patients with mild to
moderate exacerbations. Head-to-head antibiotic trials continue
to be important for COPD patients treated for exacerbations in
inpatient and ICU settings because the susceptibility of strains is
dynamic and may differ over time and from setting to setting. Fi-
nally, outcomes used in the studies included in this review are very
heterogeneous. To make studies more comparable and to interpret
them more easily in the context of other studies, a harmonised
approach to outcome measurement is needed. For example, treat-
ment failure and re-exacerbations can be defined more uniformly
and adjudicated centrally. Time horizons could be harmonised
(e.g. for treatment failure and re-exacerbations), and standard out-
comes of COPD research such as those reported on St. George’s
Respiratory Questionnaire or the Chronic Respiratory Question-
naire could be used.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Allegra 1991
Methods RCT
Participants Participants: patients recruited from pulmonary departments received antibiotic or
placebo on an outpatient basis in case of self-reportedworsening of respiratory symptoms
Inclusion criteria: aged > 40 years; chronic bronchitis (defined as continuous cough and
expectoration, present for at least 3 months of the year, in more than 2 consecutive years)
; FEV < 80% predicted
Exclusion criteria: reversible obstruction, cancer, liver insufficiency, renal insufficiency,
heart failure, pneumonia
Baseline demographics: 335 patients included; mean age 63 years; 73%male; mean FEV
1.37 L/s
Spirometrically confirmed COPD: yes
Interventions Mean follow-up: 5 days
Treatment group: amoxicillin-clavulanic acid 2 g/d (oral) for 5 days
Control group: placebo for 5 days
Outcomes Treatment success/failure (patient-reported symptoms and clinical signs) at 5 days (not
analysed in this systematic review)
Dyspnoea (not analysed in this systematic review because data were not in a format that
we could use)
Adverse events
Notes According to an author of the study (personal communication with Dr. Blasi, March
2006), data after 14 days of follow-up were obtained but were not published and were
not made available for this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
33Antibiotics for exacerbations of chronic obstructive pulmonary disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allegra 1991 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Only participants with complete follow-up were analysed
Selective reporting (reporting bias) High risk Data on treatment failure within 2 weeks were assessed but were
not reported
Intention-to-treat-analysis High risk Only participants with complete follow-up were analysed
Alonso Martinez 1992
Methods Randomised double-blinded placebo-controlled trial
Participants Participants: patients admitted to hospital with exacerbation (increasing symptoms such
as dyspnoea, sputum volume, or cough) of COPD
Inclusion criteria: clinical diagnosis of COPD at the time of hospital admission
Exclusion criteria: antibiotic treatment during the previous 2 weeks, left ventricular
failure, stroke, pneumonia, pneumothorax, non-cutaneous cancer, coma, temperature >
38°C, psychological disorders related to COPD
Baseline demographics: 90 patients included; mean age 68 years, 84% male, mean FEV
% predicted (SD) 29.98% (11.07)
Spirometrically confirmed COPD: yes
Interventions Mean follow-up: 7.2 days
Treatment group: trimethoprim-sulphamethoxazole 1.9 g/d or amoxicillin/clavulanic
acid 1.9 g/d orally for 8 days
Control group: placebo for 8 days
Outcomes Length of hospital stay
Treatment success (use of additional antibiotics)
Re-exacerbations (in 3 months - not analysed in this systematic review)
Notes All participants were treated with theophylline, inhaled bronchodilators, and oxygen. If
the numerical score was high or FEV < 40%, they received 6-methylprednisolone 0.75
mg/kg/d
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Arithmetic combination
Allocation concealment (selection bias) Low risk Randomisationwas performed through the
hospital pharmacy from which investiga-
tors received group allocation
34Antibiotics for exacerbations of chronic obstructive pulmonary disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Alonso Martinez 1992 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if outcome assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data were analysed
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
Intention-to-treat-analysis Low risk Analysed as intention to treat
Anthonisen 1987
Methods Randomised double-blinded placebo-controlled trial
Participants Participants: 173 patients with stable COPD were recruited from the community; 116
developed exacerbations (increased dyspnoea, sputum volume, or sputum purulence)
and each time were randomly assigned to receive antibiotics or placebo
Inclusion criteria: aged > 35 years; clinical diagnosis of COPD, not asthma; FEV and
FVC < 70% predicted; TLC > 80%
Exclusion criteria: FEV increased to 80% of predicted post-bronchodilator use; other
disease serious enough to influence quality of life or clinical course (e.g. cancer, left ven-
tricular failure, stroke); other disease likely to require antibiotics (e.g. recurrent sinusitis,
UTI)
Baseline demographics: 116 participants included; mean age 67 years, 80% male, mean
FEV % predicted (SD) 33.9% (13.7)
Spirometrically confirmed COPD: yes
Interventions Follow-up: 21 days
Treatment group: trimethoprim/sulphamethoxazole 1.9 g/d or amoxicillin 1 g/d or doxy-
cycline 0.1 to 0.2 g/d orally for 10 days
Control group: placebo for 10 days
Outcomes Treatment failure (patient-reported symptoms)
Side effects (% of exacerbations with side effects)
Notes Analysis was based on number of participants with first exacerbations (only first exacer-
bation). Side effects were not analysed as they were expressed as % of all exacerbations
Risk of bias
Bias Authors’ judgement Support for judgement
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Anthonisen 1987 (Continued)
Random sequence generation (selection
bias)
Low risk Random schedule
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Neither patients nor medical staff knew
which medication was active”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Medical staff ” was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data were analysed
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
Intention-to-treat-analysis Low risk Analysed as intention to treat
Berry 1960
Methods RCT
Participants Participants: patients at general practitioner visit for new or aggravated respiratory symp-
toms
Inclusion criteria: chronic bronchitis (persistent or recurrent cough with diffuse physical
signs in the chest, for which X-ray had excluded other disease) with exacerbation (wors-
ening characterised by 1 or more of the following: increased cough, increased volume of
sputum, increased purulence of sputum, increased breathlessness or fever)
Exclusion criteria: none
Baseline demographics: 58 patients included; mean age 59 years, 53% male, FEV not
reported
Spirometrically confirmed COPD: no
Interventions Mean follow-up: 14 days
Treatment group: oxytetracycline 1 g/d (oral) for 5 days
Control group: placebo for 5 days
Outcomes Treatment success/failure (patient reported)
Notes Patients with severe exacerbations were not included because antibiotics were deemed
indispensable
Risk of bias
Bias Authors’ judgement Support for judgement
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Berry 1960 (Continued)
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Low risk Identical bottles; key to numbers was kept by another person
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical bottles and capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Practitioners doing outcome assessments were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Patients with possible toxic effects from drugs were excluded
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
Intention-to-treat-analysis High risk Patients with possible toxic effects from drugs were excluded
Brusse-Keizer 2009
Methods RCT
Participants Participants: outpatients seen by chest physicians received antibiotic or placebo for mod-
erately severe exacerbations
Inclusion criteria: clinical diagnosis of COPD (GOLD criteria); current smoker or ex-
smoker; aged 40 to 80 years; presenting as an outpatient with signs and symptoms of
an exacerbation (change in dyspnoea, sputum volume and colour, and cough); able to
produce sputum sample; 1 or 2 of the following: positive sputum Gram’s stain, clinically
relevant decrease in lung function, or ≥ 2 exacerbations in the previous year
Exclusion criteria: pneumonia, exacerbation or use of antibiotics or prednisolone 4weeks
before enrolment (except≤ 5 mg prednisolone), other disease influencing lung function,
maintenance antibiotics, hypersensitivity to amoxicillin-clavulanic acid, serious medical
or psychiatric comorbidity, uncontrolled diabetes mellitus, home oxygen therapy
Baseline demographics: 35 patients included; mean age 67 years, 60% male, mean FEV
/FVC 40%
Spirometrically confirmed COPD: yes
Interventions Follow-up: 28 days for primary outcome; 4 months for new exacerbations
Treatment group: amoxicillin-clavulanic acid 1.5 g/d for 7 days and oral prednisolone
30 mg for 7 days
Control group: placebo for 7 days and oral prednisolone 30 mg for 7 days
Outcomes Resolution of exacerbation (patient-reported symptom diary)
Relapse of exacerbation within 28 days
Chronic respiratory questionnaire
Clinical COPD questionnaire
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Brusse-Keizer 2009 (Continued)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list
Allocation concealment (selection bias) Low risk Based on the randomisation list, the hospital pharmacy sequen-
tially numbered containerswith both amoxicillin/clavulanic acid
and placebo. This list was kept in a safe at the hospital pharmacy
throughout the course of the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information on blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data were analysed
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
Intention-to-treat-analysis Low risk All participants were analysed in the groups to which they were
randomised
Daniels 2010
Methods RCT
Participants Participants: hospitalised patients with acute exacerbations of COPD
Inclusion criteria: aged > 45 years, diagnosis of COPD (GOLD criteria), acute exacer-
bation (Anthonisen 1 and 2)
Exclusion criteria: inability to take oralmedication, fever (> 38.5°C), antibiotic treatment
for > 24 hours, extensive treatment with corticosteroids (> 30 mg > 4 days), history of
severe exacerbation requiring mechanical ventilation, lung malignancy, other infectious
disease requiring antibiotic therapy, heart failure (NYHA III-IV), apparent immunode-
ficiency, impaired renal function (creatinine clearance < 20 mL/min)
Baseline demographics: 223 patients included; 265 exacerbations, mean age 72 years,
59.6% male, mean FEV (SD) doxycycline group 43.9% (17.2%), placebo group 46.
9% (18.5%)
Spirometrically confirmed COPD: yes
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Daniels 2010 (Continued)
Interventions Mean follow-up: 30 days
Treatment group: 7-day course of oral doxycycline, IV prednisolone taper
Control group: 7-day course of placebo, IV prednisolone taper
Outcomes Primary outcome
Clinical response on day 30 (success/failure)
Secondary outcomes
Clinical success on day 10, dyspnoea score, adverse events, mortality
Notes Analysis based on numbers of exacerbations and participants (mortality)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated
Allocation concealment (selection bias) Low risk “Allocation sequence was kept in a safe at the hospital phar-
macy”; “study medication was delivered in pre-numbered con-
tainers”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described (only “double-blind”)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data were analysed
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
Intention-to-treat-analysis Low risk Analysed as intention to treat and per protocol (we used only
intention to treat)
Elmes 1957
Methods RCT
Participants Participants: patients were instructed to take antibiotic or placebo without a doctor visit
as soon as new or aggravated respiratory symptoms were present
Inclusion criteria: aged < 65 years; regular employment; productive winter cough for >
3 years, during which time they had at least 2 illnesses with purulent sputum, causing
loss of time from work
Exclusion criteria: other disabling disease
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Elmes 1957 (Continued)
Baseline demographics: 88 patients included; mean 54 age years, 84% male, FEV not
stated
Spirometrically confirmed COPD: no
Interventions Mean follow-up: 17 days
Treatment group: oxytetracycline 1 g/d orally for 5 to 7 days
Control group: placebo for 5 to 7 days
Outcomes Treatment success/failure (need for further antibiotics)
Time off work
Side effects
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Fisher and Yates’ table of random numbers
Allocation concealment (selection bias) Low risk “Key list was held by the hospital’s pharmacist”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Dummy tablets... neither doctors nor patients knowing which
was which”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Dummy tablets... neither doctors nor patients knowing which
was which”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data were analysed
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
Intention-to-treat-analysis Low risk Analysed as intention to treat
Fear 1962
Methods RCT
Participants Participants: patients recruited from bronchitis and asthma clinics received antibiotic or
placebo as an outpatient based on case of self-reportedworsening of respiratory symptoms
Inclusion criteria: aged 20 to 65 years; winter cough and sputum for at least 3 years, with
shortness of breath on effort without evidence of other cause; some degree of disability
from the bronchitis (e.g. limitation of normal activity, loss of time at work)
Exclusion criteria: none
Baseline demographics: 62 patients included; mean age, % male, and FEV not stated
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Fear 1962 (Continued)
Spirometrically confirmed COPD: no
Interventions Mean follow-up: 14 days
Treatment group: oxytetracycline 1 g/d (oral) for 7 days
Control group: placebo for 7 days
Outcomes Improvement in symptoms (not analysed in this systematic review)
Days of illness (not analysed in this systematic review)
Notes Second trial of the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk List of random numbers
Allocation concealment (selection bias) Low risk “Similar to that used by Elmes 1957”; “identical appearance”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”; “identical appearance”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if outcome assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data were analysed
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
Intention-to-treat-analysis Low risk Analysed as intention to treat
Hassan 2015
Methods RCT
Participants Participants: patients referred to outpatient clinics for treatment of COPD exacerbations
Inclusion criteria: type 1 exacerbation of COPD (defined as increase in dyspnoea, sputum
purulence, sputum volume)
Exclusion criteria: antibiotic treatment during last 2 weeks; other disease such as left
ventricular failure, stroke, pneumonia, pneumothorax, cancer, coma, allergy to quinolone
derivatives, concomitant infection requiring systemic antibacterial therapy
Baseline demographics: 100 patients included; mean age 62 years, 83%male, mean FEV
% predicted (SD) 54.5 (17.6) control group, 56.7 (14.0) intervention group
Spirometrically confirmed COPD: no
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Hassan 2015 (Continued)
Interventions Follow-up 21 days
Treatment group: 10-day course ciprofloxacin 500 mg twice daily or amoxicillin 500
mg/8 h
Control group: placebo for 10 days
Outcomes FEV , FVC, FEV /FVC, and peak expiratory flow rate at beginning and end of study
period
Failure rate (no resolution or deterioration of symptoms after trial of medication and at
day 21, or death)
Success rate (reduction in sputum volume and purulence measured at day 21)
Additional course of antibiotics
Improvement in dyspnoea measured at day 21 (not analysed in this review)
Change in vital signs measured at day 21
Side effects
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated inMethods section, only inDiscussion section (“dou-
ble blind”)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Information on dropouts not reported
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
Intention-to-treat-analysis Unclear risk Analysed as intention to treat, but information on dropouts, etc.
, not reported
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Jørgensen 1992
Methods Randomised double-blind placebo-controlled trial
Participants Participants: patients at general practitioner visits for new or aggravated symptoms
Inclusion criteria: aged > 18 years with acute exacerbation (subjective worsening due to
change in sputum (increased volume, change in viscosity or colour) possibly accompanied
by cough or dyspnoea, lasting longer than 3 days, or chronic bronchitis (defined as
continuous cough and expectoration), present for at least 3 months of the year, in more
than 2 consecutive years)
Exclusion criteria: pneumonia (on auscultation or X-ray), temperature > 38.5°C, heart
rate > 100 beats/min, antibiotics within previous 7 days, pregnancy, allergy to penicillin,
uncompensated heart disease, treatment with oral corticosteroids or immunosuppres-
sants
Baseline demographics: 270 patients included; mean age 60 years, 43% male, FEV
not stated
Spirometrically confirmed COPD: no
Interventions Mean follow-up: 8 days
Treatment group: amoxicillin 1.5 g (oral) for 7 days
Control group: placebo for 7 days
Outcomes Treatment failure (patient-reported symptoms)
Adverse events
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomised to treatment or
placebo”, with no other details
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not enough information
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data were analysed
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
Intention-to-treat-analysis Low risk Analysed as intention to treat
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Llor 2012
Methods Randomised double-blind placebo-controlled trial
Participants Participants recruited from 13 primary care centres
Inclusion criteria: aged >40 years, diagnosis ofmild tomoderateCOPD(smokinghistory
> 10 pack-years, ratio of post-bronchodilator FEV :FVC < 70%, post-bronchodilator
FEV > 50% of predicted value), presence of an exacerbation (at least 1 of the following:
increase in dyspnoea, increase in sputum volume, sputum purulence, or a combination)
Exclusion criteria: antibiotic use in previous 2 weeks, bronchial asthma, cystic fibrosis,
bronchiectasis of origin other than COPD, active neoplasm, tracheotomy, need for
hospital admission, immunosuppression, hypersensitivity to beta-lactams, clavulanate or
lactose, institutionalisation, unable to provide informed consent
Baseline demographics: 310 patients included; mean age 68 years, 81%male, mean FEV
/FVC 62%
Spirometrically confirmed COPD: yes
Interventions Mean follow-up: 20 days
Treatment group: amoxicillin/clavulanate 500/125 mg 3 times daily (oral) for 8 days
Control group: placebo for 8 days
Outcomes Primary outcome
Clinical cure/improvement or failure at end of therapy visit (days 9 to 11; physician
assessed)
Secondary outcomes
Clinical cure/improvement or failure at follow-up visit at day 20
Re-exacerbations
Adverse events
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table
Allocation concealment (selection bias) Unclear risk Not adequately described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients, investigators, and data assessors
were blinded to treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patients, investigators, and data assessors
were blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data were analysed
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Llor 2012 (Continued)
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
Intention-to-treat-analysis Low risk Analysed as intention to treat
Manresa 1987
Methods Randomised double-blind placebo-controlled trial
Participants Participants: patients admitted to hospital with exacerbations of COPD
Inclusion criteria: at the time of a hospital admission: increase in symptoms (cough,
dyspnoea, and volume and purulence of sputum)
Exclusion criteria: evidence of parenchymal consolidation on chest X-ray or of other
pulmonary or cardiac disease
Baseline demographics: 19 patients included; mean age 67 years, % male and FEV
not stated
Spirometrically confirmed COPD: no
Interventions Mean follow-up: 13 days
Treatment group: cefaclor 1.5 g/d (oral) for 8 days
Control group: placebo for 8 days
Outcomes Length of hospital stay
Notes Research letter to the editor
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as “double-blind” in the abstract
(exists only in the abstract)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described (“double-blind”)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data were analysed
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
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Manresa 1987 (Continued)
Intention-to-treat-analysis Low risk Analysed as intention to treat
Nouira 2001
Methods Randomised double-blind placebo-controlled trial
Participants Participants: patients admitted to medical ICU with exacerbations of COPD and need
for mechanical ventilation
Inclusion criteria: aged > 40 years; COPD diagnosed on the basis of clinical history,
physical examination, and chest radiograph; acute respiratory failure requiring mechan-
ical ventilation within first 24 hours of admission
Exclusion criteria: antimicrobial treatment in previous 10 days, alveolar infiltrates on
chest X-rays, previously enrolled in the study, known history of asthma or bronchiec-
tasis, allergy to quinolone derivatives, pregnancy or breastfeeding, terminally ill or im-
munocompromised, hepatic disease or severe renal impairment, gastrointestinal disease
that could affect drug absorption, concomitant infection requiring systemic antibacterial
therapy
Baseline demographics: 93 patients included; mean age 66 years, 90% male, mean FEV
0.77 L/s
Spirometrically confirmed COPD: no
Interventions Mean follow-up: 10 days
All participants were monitored until discharge from hospital
Treatment group: ofloxacin 400 mg/d (oral) for 10 days
Control group: placebo for 10 days
Outcomes Mortality
Treatment failure (need for additional antibiotics and death combined)
Length of hospital stay
Adverse events
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned to
treatment or placebo via random numbers
Allocation concealment (selection bias) Low risk All drugs and placebo packages were pre-
pared and numbered by the hospital phar-
macy and were used consecutively. Assign-
ments of patients were placed in closed en-
velopes with identification numbers that
were stored in the ICU
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Nouira 2001 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical appearance of the medication
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All study investigators and hospital staff
were masked to treatment status until data
completion
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data were analysed
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
Intention-to-treat-analysis Low risk Analysed as intention to treat
Petersen 1967
Methods Randomised double-blind controlled trial
Participants Participants: patients admitted to hospital with exacerbations (not defined) of COPD
Inclusion criteria: aged 45 to 75 years, chronic bronchitis (history of cough and expecto-
ration on most days during at least 3 consecutive months in each of 2 or more successive
years)
Exclusion criteria: severe deformities of the spine or chest, localised or generalised specific
lung disease, signs of cardiac insufficiency
Baseline demographics: 19 patients included; mean age 62 years, 53% male
Spirometrically confirmed COPD: no
Interventions Mean follow-up: 10 days
Treatment group: chloramphenicol 2 g/d for 10 days
Control group: placebo for 10 days
Outcomes Mortality
Patient-reported well-being
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Unclear risk Not reported
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Petersen 1967 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants: yes; personnel: no
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Control group underwent clinical exami-
nation on day 0
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropouts were not analysed
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
Intention-to-treat-analysis High risk Dropouts were not analysed (only per pro-
tocol reported)
Pines 1968
Methods Randomised double-blind placebo-controlled trial
Participants Participants: patients admitted to hospital with exacerbation of symptoms of chronic
bronchitis
Inclusion criteria: > 50 years old, history of chronic bronchitis > 5 years and history
during past 6 weeks of an exacerbation, male, moderate to severe illness on admission
(as judged by the receiving SHO), persistent purulent sputum and PEFR < 200 L/min
(unless too ill to do so)
Exclusion criteria: allergy to penicillin, asthma, extensive bronchiectasis, active tubercu-
losis, lung cancer, sputum eosinophilia (> 10%) or blood urea > 60 mg/100 mL
Baseline demographics: 30 participants; mean age 68 years, 100% males, FEV not
reported
Spirometrically confirmed COPD: no
Interventions Mean follow-up: 14 days
Treatment group: penicillin 6 million units/d for 14 days and streptomycin 1 g/d par-
enterally for 7 days
Control group: placebo for 14 days
Outcomes Treatment failure (physician reported)
Mortality
Notes Pilot trial of the paper
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Fisher and Yates’ tables
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Pines 1968 (Continued)
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Placebo injection”; “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “blind assessors”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data were analysed
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
Intention-to-treat-analysis Low risk Analysed as intention to treat
Pines 1972
Methods Randomised double-blind controlled trial
Participants Participants: patients admitted to hospital with exacerbations of COPD
Inclusion criteria: aged > 60 years, history of chronic bronchitis > 5 years and definite
history during previous 6 weeks of an exacerbation, male, failure of at least 1 previous
treatment with antibiotics, moderately severely illness on admission (as judged by the
receiving SHO), persistent purulent sputum and PEFR < 200 L/min
Exclusion criteria: asthma, bronchiectasis, other pulmonary disease, sputum eosinophilia
(> 10%)
Baseline demographics: 259 participants included; mean age 71 years, 100% male, FEV
not reported
Spirometrically confirmed COPD: no
Interventions Mean follow-up: 12 days
Exacerbations were followed at beginning and end of trial and 1 and 4 weeks later
Treatment groups 1 and 2: tetracycline hydrochloride 2 g/d or chloramphenicol 2 g/d
orally for 12 days
Control group: placebo for 12 days
Outcomes Treatment failure (physician reported) day 12
Treatment failure (additional antibiotics) days 7 to 28
Mortality
Adverse events
Notes Patients with very severe exacerbations were not included for ethical reasons
Risk of bias
Bias Authors’ judgement Support for judgement
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Pines 1972 (Continued)
Random sequence generation (selection
bias)
Low risk Fisher & Yates’ tables
Allocation concealment (selection bias) Low risk Total course of capsules for each participant
was put into a sealed bottle by an indepen-
dent pharmacist
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessments were made by independent
trained observers
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data were analysed
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
Intention-to-treat-analysis Low risk No withdrawals
Sachs 1995
Methods RCT
Participants Participants: patients at general practitioner visit for new or aggravated respiratory (in-
crease in dyspnoea with or without sputum production) symptoms
Inclusion criteria: aged > 18 years, positive diagnosis of asthma or COPD made by a
pulmonary physician during previous 10 years
Exclusion criteria: daily use of oral corticosteroids or antimicrobial drugs, diabetes mel-
litus, alcoholism, history of pulmonary surgery or tuberculosis, severe bronchiectasis, a
psychiatric history
Baseline demographics: 61 participants included; mean age ~ 52 years, %male and mean
FEV not stated
Spirometrically confirmed COPD: unclear
Interventions Mean follow-up: 35 days
Treatment group: amoxicillin 1.5 g or co-trimoxazole 1.9 g/d orally for 7 days
Control group: placebo for 7 days
Outcomes Treatment success/failure (patient-reported symptoms)
Notes We included only the subgroup with COPD
Risk of bias
Bias Authors’ judgement Support for judgement
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Sachs 1995 (Continued)
Random sequence generation (selection
bias)
Low risk List of random numbers
Allocation concealment (selection bias) Low risk Hospital pharmacist had the code of allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data were analysed
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
Intention-to-treat-analysis Low risk Analysed as intention to treat
van Velzen 2017
Methods RCT
Participants Participants: patients with exacerbations at outpatient clinics or primary care centres
Inclusion criteria: ≥ 45 years; smoking history ≥ 10 pack-years; diagnosis of mild to
severe COPD, defined as post-bronchodilator FEV /FVC of 0.7 or lower and post-
bronchodilator FEV of at least 30%, according to GOLD stages 1 to 3; at least 1
exacerbation during past 3 years (not in last 4 weeks)
Exclusion criteria: poor mastery of language, poor cognitive functioning, known allergy
to doxycycline, pregnancy, life expectancy shorter than 1month, fever (> 38.5°C), hospi-
tal admission, current use of antibiotics, use of antibiotics for respiratory tract infection
in previous 3 weeks
Baseline demographics: 301 patients included; mean age 66 years, 60%male, mean FEV
% predicted (SD) 60.6 (17.8)
Spirometrically confirmed COPD: yes
Interventions Follow-up: 2 years
Treatment group: oral doxycycline 100 mg daily (200 mg on first day) for 7 days
Control group: placebo for 7 days
Outcomes Primary outcome
Time between first exacerbation and next exacerbation
Secondary outcomes
Treatment failure at day 21 and day 84 (late follow-up)
Mortality
Number of exacerbations
COPD-specific health status (SGRQ)
51Antibiotics for exacerbations of chronic obstructive pulmonary disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
van Velzen 2017 (Continued)
Decline in lung volume (post-bronchodilator FEV and FVC) at end of follow-up
Total antibiotic use
Adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Automated and centralised randomisation service
Allocation concealment (selection bias) Low risk Automated and centralised randomisation service
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and investigators were masked to treatment assign-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Those assessing outcomes were masked to treatment assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data were analysed
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
Intention-to-treat-analysis Low risk Analysed as intention to treat
Wang 2016
Methods RCT
Participants Participants: hospitalised patients with acute exacerbations of COPD and low procalci-
tonin
Inclusion criteria: aged > 40 years, sound understanding and language abilities, PCT
level < 0.1 ng/mL
Exclusion criteria: fever (≥ 38°C), tracheal intubation within 24 hours after hospital
admission, PCT level≥ 0.1 ng/mL, pneumonia, chronic renal failure, history of malig-
nant disease, immunosuppressive therapy, refusal to participate
Baseline demographics: 194 patients included; mean age 73 years, 71%male, mean FEV
% predicted (SD) antibiotics group 36.7 (15.8), placebo group 38.4 (16.5)
Spirometrically confirmed COPD: yes
Interventions Mean follow-up: 30 days
Treatment group: piperacillin-sulbactam; ceftazidine or levofloxacin in case of allergy
(duration determined by physician)
Control group: placebo for 7 days
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Wang 2016 (Continued)
Outcomes Primary outcome
Treatment success rate on day 10 after admission
Secondary outcomes
Symptoms assessed by VAS (at hospital admission, 3 days after hospitalisation, on the
day of hospital discharge)
Length of hospital stay
Intubation rate
Mortality during hospitalisation and in the 30-day follow-up period
Rate of antibiotic use
Re-admission due to AECOPD within 30-day follow-up
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer digital table method
Allocation concealment (selection bias) Low risk Stated that it was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not exactly stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data were analysed
Selective reporting (reporting bias) Unclear risk Unclear if all outcome data were reported
Intention-to-treat-analysis Low risk Analysed as intention to treat
AECOPD: acute exacerbation of COPD; COPD: chronic obstructive pulmonary disease; FEV : forced expiratory volume in one
second; FVC: forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; ICU: intensive care unit; IV:
intravenous; NYHA: New York Heart Association; PCT: procalcitonin testing; PEFR: peak expiratory flow rate; RCT: randomised
controlled trial; SD: standard deviation; SGRQ: St. George’s Respiratory Questionnaire; SHO: senior house officer; TLC: total lung
capacity; UTI: urinary tract infection; VAS: visual analogue scale
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aitchison 1968 No placebo group
Alix 1979 No placebo group
Allan 1966 No placebo group
Allegra 1996 No placebo group
Alvarez-Sala 2006 No placebo group
Andrijevic 2011 No comparison group
Anon 1969 No placebo group
Anon 1972 No placebo group
Banerjee 2001 No COPD exacerbations
Bekçi 2009 Participants did not have an exacerbation of COPD (stable patients)
Bennion-Pedley 1969 No placebo group
Braendli 1982 No placebo group
Burgi 1975 No placebo group
Burrow 1975 No placebo group
Chatterjee 2011 No placebo group
Chen 2000 No placebo group
Christiansen 1963 No placebo group
Citron 1969 Not an RCT
Dong 2005 No placebo group
Douglas 1957 Not randomised and study had no placebo group
Egede 1993 No placebo group
Elmes 1965 Not randomised. Matched pairs
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Fartoukh 2004 Protocol. Trial not initiated due to recruitment problems
Filipovic 2000 No placebo group
Francis 1960 Use of long-term prophylactic antibiotics
Francis 1964 No placebo group
Fruensgaard 1972 No placebo group
Gaillat 2007 No placebo group
Gocke 1964 No placebo group
Goddard 2003 Not an RCT
Gomez 2000 Prophylactic antibiotic use. Participants were treated with azithromycin 500 mg/d for 3 days every 21 days
during the winter months, and a control group was given no treatment
Gotfried 2007 No placebo group
Guerin 1987 No placebo group
Haanaes 1980 No placebo group
Hansen 1986 Not an RCT
Hansen 1990 No clinical outcomes
Hauke 2002 No placebo group
Hopkins 1962 No placebo group
Jacobsen 2002 Not an RCT, but a retrospective chart review
Jia 2010 No placebo group
Johnston 1961 Study assessed outcomes of long-term antibiotic use in stable patients (no exacerbation)
Kaul 1967 No placebo group
King 1996 Study not in patients with COPD, but in patients with acute bronchitis
Leophonte 1998 Study not in patients with COPD, but in patients with acute bronchitis
Lirsac 2000 No placebo group. In addition, the antibiotic treatment group received fenspiride (from day 0 to day 30)
and the control group received a placebo
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Maesen 1976 No placebo group
Maesen 1980 No placebo group
Malone 1968 No placebo group
May 1964 No placebo group
Miravitlles 2009 Study compared participants with stable disease (no exacerbation)
NCT00255983 This study terminated early (financial reasons) and results were never published
Nicotra 1982 No clinical outcomes
Nonikov 2001 No placebo group
Parnham 2005 Study looked at participants with stable disease (no exacerbation)
Peng 2003 Not an RCT, but a retrospective cohort study
Pham 1964 Not an RCT
Pines 1967 No placebo group
Pines 1969 No placebo group
Pines 1972a No placebo group
Pines 1973 No placebo group
Pines 1973a No placebo group
Pines 1974 Not an RCT
PRITZL 1959 Not an RCT
Puchelle 1975 No placebo group
Pugh 1964 No placebo group
Rethly 1961 Not an RCT
Roede 2007 Placebo group began after 3 days of antibiotics in both groups
Romanovskikh 2007 No placebo group
Ross 1973 No placebo group
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Sethi 2007 No placebo group
Sethi 2010 Study looked at participants with stable disease (no exacerbation)
Smyllie 1972 No placebo group
Sohy 2002 Not an RCT, but a narrative review
Soler 2003 No placebo group
Soltaninejad 2016 Nebulised antibiotics
Stolz 2007 No placebo group
Suzuki 2001 Prophylactic antibiotic use
Tremolieres 2000 No placebo group
Williams 1981 No placebo group
Wilson 2004 No placebo group in the trial. Moxifloxacin was compared to standard antibiotic therapy
Wilson 2011 No placebo group
Wilson 2012 Head-to-head trial of 2 different antibiotic regimens
Zapulla 1988 No placebo group
Zervos 2005 No placebo group
COPD: chronic obstructive pulmonary disease; RCT: randomised controlled trial.
Characteristics of ongoing studies [ordered by study ID]
NCT01091493
Trial name or title Utility of antibiotic treatment in non-purulent exacerbations of chronic obstructive pulmonary disease: a
double-blinded, randomized, placebo-controlled trial of security and efficacy (AEPOC-ATB)
Methods RCT
Participants Inclusion criteria: aged 40 to 90 years; COPD diagnosis according to GOLD guidelines; hospitalisation
for any acute exacerbation of COPD; failure of outpatient treatment, increasing dyspnoea in previous days;
comorbidity that caused detriment to respiratory function
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NCT01091493 (Continued)
Exclusion criteria: life expectancy < 6 months; mechanical ventilation; cardiovascular condition that causes
exacerbation; immunosuppression; pulmonary infiltrates that suggest pneumonia; antibiotic treatment in the
last month; pregnancy; ECG with a large QT segment; hypokalaemia; hepatic failure or renal failure
Interventions Drug: moxifloxacin 400 mg administered once a day for 5 days
Control: no intervention
Outcomes Primary outcome measures: efficacy of treatment WITHOUT antibiotics in non-purulent exacerbations of
COPD (time frame: 6 months)
Secondary outcome measures: efficacy/safety in treatment on re-hospitalisation at 6 months (time frame: 6
months); in-hospital stay (days) (time frame: 6 months); all-cause mortality (time frame: 1 and 6 months)
; determination of procalcitonin (time frame: hospitalisation day 1, 1 month, and 6 months); quality of
life measured by St. George’s Respiratory Questionnaire (time frame: hospitalisation day 1 and 6 months);
measure of CRP (time frame: hospitalisation day 1, 1 month, and 6 months); measure of cytokines (IL-1, IL-
6, IL-8, IL-10) (time frame: hospitalisation day 1, 1 month, and 6 months); measure of TNF-α (time frame:
hospitalisation day 1, 1 month, and 6 months)
Starting date July 2010
Contact information Nestor Soler, MD, PhD; email:nsoler@clinic.ub.es
Notes -
NCT01892488
Trial name or title Randomized double-blind placebo-controlled study to demonstrate that antibiotics are not needed in mod-
erate acute exacerbations of COPD - the ABACOPD Study
Methods RCT
Participants Inclusion criteria:
• Adults, either sex, 40 years of age and older
• For female patients, the following conditions are to be met: has been postmenopausal for at least 1
year, or is surgically incapable of bearing children, or is of childbearing potential, and the following
conditions are met: has a negative pregnancy test (urine- or serum-based) immediately before study entry (i.
e. before the start of treatment or any other study procedure that could potentially harm the foetus), and 1
or more of following criteria: must agree to abstinence or use an accepted method of contraception. The
patient must agree to continue with the same method throughout the study, having only female sexual
partners or sexual relationships with sterile male partners only
• Patients with diagnosis of COPD stages I to IV as defined by the Global Initiative for Chronic
Obstructive Lung Disease (GOLD)
and
• Doctor’s diagnosis of acute (onset < 7 days) moderate exacerbation of COPD defined by sustained
worsening of the patient’s condition (including at least 2 of the following symptoms: increased dyspnoea,
increased sputum production, sputum purulence, and increased cough), from the stable state and beyond
normal day-to-day variations, necessitating a change in regular medication in patients with underlying
COPD needing additional medical assistance
• Absence of community-acquired pneumonia or lower respiratory tract infection with a clear indication
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NCT01892488 (Continued)
for antibiotic treatment as determined by procalcitonin level < 0.25 ng/mL and/or absence of pulmonary
infiltrates on routine chest X-ray
• Smoking history of 10 or more pack-years
• Must be able to complete diaries and quality of life questionnaires
• Must sign and date an informed consent before beginning any study procedures
Interventions Placebo vs sultamicillin
Outcomes Antibiotic therapy added to study medication during treatment period or until the test of cure visit (at day
30)
Relapse rate
Time to relapse
Clinical cure rate at the “end of therapy visit” (at day 6)
Clinical cure rate at the “test of cure visit” (at day 30)
Changes in CAT
Changes in Exacerbations of Chronic Pulmonary Disease Tool-Patient Reported Outcome (EXACT-PRO)
Additional antibiotic therapy
Time to next exacerbation
Number of exacerbations during follow-up
Per-participant relapse rate at LFU (late follow-up) visits in the subset of participants who were clinically
cured at the TOC visit
Changes in length of stay in hospital for hospitalised participants
All-cause mortality
Starting date June 2013
Contact information Grit Barten: grit.barten@capnetz.de
Waldemar Kroener: waldemar.kroener@capnetz.de
Notes
NCT03262142
Trial name or title Targeted antibiotics for chronic obstructive pulmonary disease (Target-ABC)
Methods RCT
Participants Inclusion criteria:
• Adults of either sex 40 years of age and older
• 1 positive sputum sample for P aeruginosa
• COPD (verified by pulmonologist based on clinical and spirometric criteria)
• Minimum 1 previous AECOPD requiring hospitalisation/emergency department visit and
administration of systemic prednisolone ± antibiotic treatment within the last 12 months
• Completed and signed informed consent
Exclusion criteria:
• Immune-modulating therapy (except ≤ 5 mg prednisolone/d)
• Men < 40 years
• Women < 55 years
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• Non-menopausal women > 55 years
• Life expectancy < 90 days
• Severe mental illness
• Severe language difficulties or inability to provide informed consent
• Known drug allergy to (1) fluoroquinolones or (2) piperacillin/tazobactam, cephalosporins, and
carbapenems
• Attempted eradication of P aeruginosa × 2 within the last 12 months, or completed eradication therapy
within the last 14 days
• Investigator ’s opinion is that the participant requires antibiotic treatment. This exclusion criterion
must be discussed with the co-ordinating investigator before the final decision on exclusion is made
• Has had menstruation within the last 12 months
• Treatment with same antibiotics as used in the trial
Interventions Intravenous piperacillin/tazobactam + oral ciprofloxacin for 14 days vs no antibiotic treatment
Outcomes Primary: time to systemic corticosteroid and/or antibiotic requiringAECOPD(in both primary and secondary
sectors) or death
Secondary: alive and without AECOPD; death; microbiological cure; clinical cure; number of re-admissions
with AECOPD; number of days with non-invasive ventilation (NIV) or respiratory therapy; change in FEV
; fall in FEV ≥ 200 mL/y; change in COPD assessment test (CAT); changes in body mass index (BMI)
Starting date January 2018
Contact information Josefin Eklof; josefin.viktoria.ekloef@regionh.dk
Notes
AECOPD: acute exacerbation of COPD; BMI: bodymass index; CAT:COPDAssessmentTest; COPD: chronic obstructive pulmonary
disease; CRP: C-reactive protein; ECG: electrocardiogram; EXACT-PRO: Exacerbations of Chronic Pulmonary Disease Tool-
Patient Reported Outcome; FEV : forced expiratory volume in one second; GOLD: Global Initiative for Chronic Obstructive
Lung Disease; IL: interleukin; LFU: late follow-up; NIV: non-invasive ventilation; P aeruginosa: Pseudomonas aeruginosa; RCT:
randomised controlled trial; TNF-α: tumour necrosis factor-alpha; TOC: Test of Cure.
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D A T A A N D A N A L Y S E S
Comparison 1. Antibiotics versus placebo: outpatients
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Treatment failure up to 4 weeks
(no resolution or deterioration
after trial medication of any
duration or death when
explicitly stated due to
exacerbation or additional
course of antibiotics)
9 1332 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.53, 0.90]
2 Treatment failure within 4 weeks
- current drugs only
7 1191 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.56, 0.94]
3 All-cause mortality 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
4 Re-exacerbations within ≥ 2
to 6 weeks since beginning of
index exacerbation (rates)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Improvement in dyspnoea
measured at the end of the
study period
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 Health-related quality of life or
functional status measures
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7 Days off work 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 2. Antibiotics versus placebo: inpatients
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Treatment failure up to 4 weeks
(no resolution or deterioration
after trial medication of any
duration or death when
explicitly stated due to
exacerbation or additional
course of antibiotics)
6 896 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.39, 0.91]
1.1 Inpatient 5 803 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.58, 1.00]
1.2 ICU 1 93 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.08, 0.45]
2 Treatment failure within 4 weeks
- current drugs only
4 576 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.38, 1.12]
2.1 Inpatient 4 576 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.38, 1.12]
3 All-cause mortality 3 507 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.95 [0.45, 2.02]
3.1 Inpatients 2 414 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.48 [0.94, 6.55]
3.2 ICU patients 1 93 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.21 [0.06, 0.72]
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4 Duration of hospital stay (days) 4 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Inpatients 3 300 Mean Difference (IV, Random, 95% CI) 0.09 [-0.79, 0.96]
4.2 ICU 1 93 Mean Difference (IV, Random, 95% CI) -9.6 [-12.84, -6.36]
5 Re-exacerbations within ≥ 2
to 6 weeks since beginning of
index exacerbation (rates)
2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 Improvement in dyspnoea
measured at the end of the
study period
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Inpatients 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Health-related quality of life or
functional status measures
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8 Days off work 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 3. Antibiotics versus placebo: adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse events 7 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Diarrhoea 5 1099 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.68 [0.92, 3.07]
1.2 Dyspepsia 3 705 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.66 [0.28, 1.55]
1.3 Pain in mouth 1 270 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.73 [0.80, 74.98]
1.4 Exanthema, itching 4 798 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.26 [0.65, 7.87]
1.5 Overall (adverse events
not separated)
6 1544 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.20 [0.89, 1.63]
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Analysis 1.1. Comparison 1 Antibiotics versus placebo: outpatients, Outcome 1 Treatment failure up to 4
weeks (no resolution or deterioration after trial medication of any duration or death when explicitly stated
due to exacerbation or additional course of antibiotics).
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 1 Antibiotics versus placebo: outpatients
Outcome: 1 Treatment failure up to 4 weeks (no resolution or deterioration after trial medication of any duration or death when explicitly stated due to exacerbation
or additional course of antibiotics)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berry 1960 0/26 5/27 0.9 % 0.09 [ 0.01, 1.62 ]
Sachs 1995 (1) 4/40 2/21 2.5 % 1.05 [ 0.21, 5.27 ]
Brusse-Keizer 2009 (2) 3/18 3/17 3.1 % 0.94 [ 0.22, 4.05 ]
Elmes 1957 (3) 4/42 9/46 5.1 % 0.49 [ 0.16, 1.46 ]
Hassan 2015 6/50 15/50 7.7 % 0.40 [ 0.17, 0.95 ]
Llor 2012 (4) 15/158 30/152 14.0 % 0.48 [ 0.27, 0.86 ]
Anthonisen 1987 (5) 19/57 28/59 18.7 % 0.70 [ 0.45, 1.11 ]
van Velzen 2017 (6) 32/150 46/151 21.8 % 0.70 [ 0.47, 1.03 ]
J rgensen 1992 (7) 49/132 49/136 26.1 % 1.03 [ 0.75, 1.41 ]
Total (95% CI) 673 659 100.0 % 0.69 [ 0.53, 0.90 ]
Total events: 132 (Antibiotics), 187 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 11.60, df = 8 (P = 0.17); I2 =31%
Test for overall effect: Z = 2.70 (P = 0.0068)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours antibiotic Favours placebo
(1) failure between 4-24 days
(2) 28 days,
(3) time point unclear;reported for exacerbations only.under the assumption that it happened to every pat once we took patients instead
(4) 20 days
(5) within 21 days
(6) 21 days
(7) day 8
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Analysis 1.2. Comparison 1 Antibiotics versus placebo: outpatients, Outcome 2 Treatment failure within 4
weeks - current drugs only.
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 1 Antibiotics versus placebo: outpatients
Outcome: 2 Treatment failure within 4 weeks - current drugs only
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Anthonisen 1987 (1) 19/57 28/59 19.8 % 0.70 [ 0.45, 1.11 ]
Brusse-Keizer 2009 (2) 3/18 3/17 3.0 % 0.94 [ 0.22, 4.05 ]
Hassan 2015 (3) 6/50 15/50 7.8 % 0.40 [ 0.17, 0.95 ]
J rgensen 1992 (4) 49/132 49/136 28.8 % 1.03 [ 0.75, 1.41 ]
Llor 2012 (5) 15/158 30/152 14.5 % 0.48 [ 0.27, 0.86 ]
Sachs 1995 (6) 4/40 2/21 2.5 % 1.05 [ 0.21, 5.27 ]
van Velzen 2017 (7) 32/150 46/151 23.6 % 0.70 [ 0.47, 1.03 ]
Total (95% CI) 605 586 100.0 % 0.72 [ 0.56, 0.94 ]
Total events: 128 (Antibiotics), 173 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 8.76, df = 6 (P = 0.19); I2 =31%
Test for overall effect: Z = 2.42 (P = 0.016)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antibiotics Favours placebo
(1) within 21 days
(2) 28 days
(3) day 21
(4) day 8
(5) 20 days
(6) failure between 4-24 days
(7) day 21
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Analysis 1.3. Comparison 1 Antibiotics versus placebo: outpatients, Outcome 3 All-cause mortality.
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 1 Antibiotics versus placebo: outpatients
Outcome: 3 All-cause mortality
Study or subgroup Antibiotics Placebo
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
van Velzen 2017 10/150 8/151 1.27 [ 0.49, 3.30 ]
0.001 0.01 0.1 1 10 100 1000
Favours antibiotics Favours placebo
Analysis 1.4. Comparison 1 Antibiotics versus placebo: outpatients, Outcome 4 Re-exacerbations within ≥
2 to 6 weeks since beginning of index exacerbation (rates).
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 1 Antibiotics versus placebo: outpatients
Outcome: 4 Re-exacerbations within≥ 2 to 6 weeks since beginning of index exacerbation (rates)
Study or subgroup Antibiotics Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brusse-Keizer 2009 (1) 2/18 1/17 1.89 [ 0.19, 18.97 ]
0.01 0.1 1 10 100
Favours antibiotics Favours placebo
(1) relapse within 4 weeks
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Analysis 1.5. Comparison 1 Antibiotics versus placebo: outpatients, Outcome 5 Improvement in dyspnoea
measured at the end of the study period.
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 1 Antibiotics versus placebo: outpatients
Outcome: 5 Improvement in dyspnoea measured at the end of the study period
Study or subgroup Antibiotics Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Brusse-Keizer 2009 18 0.5 (1.3) 17 0.5 (1.6) 0.0 [ -0.97, 0.97 ]
-2 -1 0 1 2
Favours antibiotics Favours placebo
Analysis 1.6. Comparison 1 Antibiotics versus placebo: outpatients, Outcome 6 Health-related quality of
life or functional status measures.
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 1 Antibiotics versus placebo: outpatients
Outcome: 6 Health-related quality of life or functional status measures
Study or subgroup Antibiotics Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Brusse-Keizer 2009 (1) 18 -2.3 (2.7) 17 -2.3 (2.7) 0.0 [ -1.79, 1.79 ]
-4 -2 0 2 4
Favours antibiotics Favours placebo
(1) CCQ
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Analysis 1.7. Comparison 1 Antibiotics versus placebo: outpatients, Outcome 7 Days off work.
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 1 Antibiotics versus placebo: outpatients
Outcome: 7 Days off work
Study or subgroup Antibiotics Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Elmes 1957 42 4.25 (0.96) 46 9.43 (2.96) -5.18 [ -6.08, -4.28 ]
-4 -2 0 2 4
Favours antibiotics Favours placebo
Analysis 2.1. Comparison 2 Antibiotics versus placebo: inpatients, Outcome 1 Treatment failure up to 4
weeks (no resolution or deterioration after trial medication of any duration or death when explicitly stated
due to exacerbation or additional course of antibiotics).
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 2 Antibiotics versus placebo: inpatients
Outcome: 1 Treatment failure up to 4 weeks (no resolution or deterioration after trial medication of any duration or death when explicitly stated due to exacerbation
or additional course of antibiotics)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Inpatient
Wang 2016 (1) 6/95 4/96 8.3 % 1.52 [ 0.44, 5.20 ]
Alonso Martinez 1992 4/61 6/29 8.8 % 0.32 [ 0.10, 1.04 ]
Pines 1968 5/15 12/15 15.1 % 0.42 [ 0.20, 0.89 ]
Daniels 2010 (2) 50/128 65/137 26.6 % 0.82 [ 0.62, 1.09 ]
Pines 1972 (3) 93/160 46/67 28.1 % 0.85 [ 0.69, 1.04 ]
Subtotal (95% CI) 459 344 86.9 % 0.76 [ 0.58, 1.00 ]
Total events: 158 (Antibiotics), 133 (Placebo)
0.05 0.2 1 5 20
Favours antibiotics Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.03; Chi2 = 6.57, df = 4 (P = 0.16); I2 =39%
Test for overall effect: Z = 1.97 (P = 0.049)
2 ICU
Nouira 2001 5/47 26/46 13.1 % 0.19 [ 0.08, 0.45 ]
Subtotal (95% CI) 47 46 13.1 % 0.19 [ 0.08, 0.45 ]
Total events: 5 (Antibiotics), 26 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.78 (P = 0.00016)
Total (95% CI) 506 390 100.0 % 0.60 [ 0.39, 0.91 ]
Total events: 163 (Antibiotics), 159 (Placebo)
Heterogeneity: Tau2 = 0.15; Chi2 = 18.22, df = 5 (P = 0.003); I2 =73%
Test for overall effect: Z = 2.42 (P = 0.015)
Test for subgroup differences: Chi2 = 9.12, df = 1 (P = 0.00), I2 =89%
0.05 0.2 1 5 20
Favours antibiotics Favours placebo
(1) 10 days
(2) day 30
(3) additional antibiotics (day 7-28)
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Analysis 2.2. Comparison 2 Antibiotics versus placebo: inpatients, Outcome 2 Treatment failure within 4
weeks - current drugs only.
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 2 Antibiotics versus placebo: inpatients
Outcome: 2 Treatment failure within 4 weeks - current drugs only
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Inpatient
Wang 2016 6/95 4/96 14.0 % 1.52 [ 0.44, 5.20 ]
Alonso Martinez 1992 4/61 6/29 14.8 % 0.32 [ 0.10, 1.04 ]
Pines 1968 5/15 12/15 25.6 % 0.42 [ 0.20, 0.89 ]
Daniels 2010 (1) 50/128 65/137 45.6 % 0.82 [ 0.62, 1.09 ]
Total (95% CI) 299 277 100.0 % 0.65 [ 0.38, 1.12 ]
Total events: 65 (Antibiotics), 87 (Placebo)
Heterogeneity: Tau2 = 0.15; Chi2 = 6.01, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antibiotics Favours placebo
(1) day 30
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Analysis 2.3. Comparison 2 Antibiotics versus placebo: inpatients, Outcome 3 All-cause mortality.
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 2 Antibiotics versus placebo: inpatients
Outcome: 3 All-cause mortality
Study or subgroup Antibiotics Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Inpatients
Wang 2016 5/95 2/96 25.2 % 2.45 [ 0.54, 11.04 ]
Daniels 2010 7/107 3/116 35.6 % 2.51 [ 0.71, 8.90 ]
Subtotal (95% CI) 202 212 60.8 % 2.48 [ 0.94, 6.55 ]
Total events: 12 (Antibiotics), 5 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.066)
2 ICU patients
Nouira 2001 2/47 10/46 39.2 % 0.21 [ 0.06, 0.72 ]
Subtotal (95% CI) 47 46 39.2 % 0.21 [ 0.06, 0.72 ]
Total events: 2 (Antibiotics), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.012)
Total (95% CI) 249 258 100.0 % 0.95 [ 0.45, 2.02 ]
Total events: 14 (Antibiotics), 15 (Placebo)
Heterogeneity: Chi2 = 9.62, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 0.13 (P = 0.89)
Test for subgroup differences: Chi2 = 9.62, df = 1 (P = 0.00), I2 =90%
0.001 0.01 0.1 1 10 100 1000
Favours antibiotics Favours placebo
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Analysis 2.4. Comparison 2 Antibiotics versus placebo: inpatients, Outcome 4 Duration of hospital stay
(days).
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 2 Antibiotics versus placebo: inpatients
Outcome: 4 Duration of hospital stay (days)
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Inpatients
Manresa 1987 11 12.8 (4) 8 12.3 (4) 5.8 % 0.50 [ -3.14, 4.14 ]
Wang 2016 95 10.9 (8.1) 96 9.9 (5.1) 20.7 % 1.00 [ -0.92, 2.92 ]
Alonso Martinez 1992 61 7.9 (2.1) 29 8.1 (2.4) 73.5 % -0.20 [ -1.22, 0.82 ]
Subtotal (95% CI) 167 133 100.0 % 0.09 [ -0.79, 0.96 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.22, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
2 ICU
Nouira 2001 47 14.9 (7.4) 46 24.5 (8.5) 100.0 % -9.60 [ -12.84, -6.36 ]
Subtotal (95% CI) 47 46 100.0 % -9.60 [ -12.84, -6.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.80 (P < 0.00001)
Test for subgroup differences: Chi2 = 31.99, df = 1 (P = 0.00), I2 =97%
-10 -5 0 5 10
Favours antibiotics Favours placebo
71Antibiotics for exacerbations of chronic obstructive pulmonary disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.5. Comparison 2 Antibiotics versus placebo: inpatients, Outcome 5 Re-exacerbations within ≥ 2
to 6 weeks since beginning of index exacerbation (rates).
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 2 Antibiotics versus placebo: inpatients
Outcome: 5 Re-exacerbations within≥ 2 to 6 weeks since beginning of index exacerbation (rates)
Study or subgroup Antibiotics Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brusse-Keizer 2009 (1) 2/18 1/17 1.89 [ 0.19, 18.97 ]
Wang 2016 17/95 11/96 1.56 [ 0.77, 3.16 ]
0.01 0.1 1 10 100
Favours antibiotics Favours placebo
(1) relapse within 4 weeks
Analysis 2.6. Comparison 2 Antibiotics versus placebo: inpatients, Outcome 6 Improvement in dyspnoea
measured at the end of the study period.
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 2 Antibiotics versus placebo: inpatients
Outcome: 6 Improvement in dyspnoea measured at the end of the study period
Study or subgroup Antibiotics Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Inpatients
Daniels 2010 128 -2.4 (2.8) 137 -1.8 (2.8) -0.60 [ -1.27, 0.07 ]
-2 -1 0 1 2
Favours antibiotics Favours placebo
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Analysis 2.7. Comparison 2 Antibiotics versus placebo: inpatients, Outcome 7 Health-related quality of life
or functional status measures.
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 2 Antibiotics versus placebo: inpatients
Outcome: 7 Health-related quality of life or functional status measures
Study or subgroup Antibiotics Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Brusse-Keizer 2009 (1) 18 -2.3 (2.7) 17 -2.3 (2.7) 0.0 [ -1.79, 1.79 ]
-4 -2 0 2 4
Favours antibiotics Favours placebo
(1) CCQ
Analysis 2.8. Comparison 2 Antibiotics versus placebo: inpatients, Outcome 8 Days off work.
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 2 Antibiotics versus placebo: inpatients
Outcome: 8 Days off work
Study or subgroup Antibiotics Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Elmes 1957 42 4.25 (0.96) 46 9.43 (2.96) -5.18 [ -6.08, -4.28 ]
-4 -2 0 2 4
Favours antibiotics Favours placebo
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Analysis 3.1. Comparison 3 Antibiotics versus placebo: adverse events, Outcome 1 Adverse events.
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 3 Antibiotics versus placebo: adverse events
Outcome: 1 Adverse events
Study or subgroup Antibiotics Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Diarrhoea
Nouira 2001 1/47 1/46 4.6 % 0.98 [ 0.06, 15.89 ]
Allegra 1991 2/176 1/159 7.0 % 1.77 [ 0.18, 17.17 ]
Hassan 2015 3/50 2/50 11.2 % 1.52 [ 0.25, 9.08 ]
J rgensen 1992 13/133 4/137 37.4 % 3.18 [ 1.19, 8.48 ]
van Velzen 2017 9/150 9/151 39.8 % 1.01 [ 0.39, 2.61 ]
Subtotal (95% CI) 556 543 100.0 % 1.68 [ 0.92, 3.07 ]
Total events: 28 (Antibiotics), 17 (Placebo)
Heterogeneity: Chi2 = 2.90, df = 4 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.088)
2 Dyspepsia
Hassan 2015 1/50 2/50 13.8 % 0.51 [ 0.05, 4.98 ]
J rgensen 1992 3/133 6/137 40.8 % 0.52 [ 0.14, 1.95 ]
Allegra 1991 5/176 5/159 45.4 % 0.90 [ 0.26, 3.17 ]
Subtotal (95% CI) 359 346 100.0 % 0.66 [ 0.28, 1.55 ]
Total events: 9 (Antibiotics), 13 (Placebo)
Heterogeneity: Chi2 = 0.41, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
3 Pain in mouth
J rgensen 1992 3/133 0/137 100.0 % 7.73 [ 0.80, 74.98 ]
Subtotal (95% CI) 133 137 100.0 % 7.73 [ 0.80, 74.98 ]
Total events: 3 (Antibiotics), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
4 Exanthema, itching
Allegra 1991 1/176 0/159 10.1 % 6.71 [ 0.13, 339.81 ]
Nouira 2001 1/47 0/46 10.2 % 7.23 [ 0.14, 364.63 ]
Hassan 2015 2/50 2/50 39.5 % 1.00 [ 0.14, 7.32 ]
J rgensen 1992 3/133 1/137 40.2 % 2.83 [ 0.39, 20.34 ]
Subtotal (95% CI) 406 392 100.0 % 2.26 [ 0.65, 7.87 ]
0.001 0.01 0.1 1 10 100 1000
Favours antibiotics Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Antibiotics Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Total events: 7 (Antibiotics), 3 (Placebo)
Heterogeneity: Chi2 = 1.33, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
5 Overall (adverse events not separated)
Nouira 2001 5/42 4/42 4.9 % 1.28 [ 0.32, 5.06 ]
Daniels 2010 4/133 5/125 5.2 % 0.75 [ 0.20, 2.81 ]
Allegra 1991 8/168 6/153 8.1 % 1.22 [ 0.42, 3.57 ]
Llor 2012 23/158 12/152 18.8 % 1.94 [ 0.96, 3.92 ]
J rgensen 1992 27/133 18/137 22.7 % 1.67 [ 0.88, 3.17 ]
van Velzen 2017 47/150 53/151 40.4 % 0.84 [ 0.52, 1.36 ]
Subtotal (95% CI) 784 760 100.0 % 1.20 [ 0.89, 1.63 ]
Total events: 114 (Antibiotics), 98 (Placebo)
Heterogeneity: Chi2 = 5.40, df = 5 (P = 0.37); I2 =7%
Test for overall effect: Z = 1.19 (P = 0.23)
0.001 0.01 0.1 1 10 100 1000
Favours antibiotics Favours placebo
A D D I T I O N A L T A B L E S
Table 1. Type and dose of antibiotic used
Study Antibiotic Dose (g/d) Duration
(days)
Currently
available and
used?
Co-
interventions
Control Setting
Allegra 1991 Amoxicillin-
clavulanic acid
(oral)
2 5 Yes Placebo Outpatient
Alonso
Martinez
1992
Trimetho-
prim-sul-
phamethoxa-
zole or amoxi-
cillin-clavu-
lanic acid
1.9 8 Yes Prednisone Placebo and
prednisone
Hospital
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Table 1. Type and dose of antibiotic used (Continued)
Anthonisen
1987
Trimetho-
prim/sul-
phamethoxa-
zole (oral)
1.9 10 Yes Placebo Outpatient
Amoxicillin
(oral)
1
Doxycycline
(oral)
0.1-0.2
Berry 1960 Oxytetracy-
cline (oral)
1 g/d 5 No Placebo Outpatient
Brusse-Keizer
2009
Amoxicillin-
clavulanic acid
(oral)
1.5 7 Yes Oral pred-
nisolone 30
mg for 7 days
Placebo for 7
days and oral
prednisolone
30 mg for 7
days
Outpatient
Daniels 2010 Doxycycline
(oral)
Not stated 7 Yes IV pred-
nisolone taper
Placebo
plus IV pred-
nisolone taper
Hospital
Elmes 1957 Oxytetracy-
cline (oral)
1 5-7 No Placebo Outpatient
Fear 1962 Oxytetracy-
cline (oral)
1 7 No Placebo Outpatient
Hassan 2015 Ciprofloxacin
(oral)
1 10 Yes Oral
prednisolone
40 mg/d for 3
days followed
by 5-10 mg
for 12 days if
steroid respon-
sive
Placebo Outpatient
Amoxicillin
(oral)
1.5
Jørgensen
1992
Amoxicillin
(oral)
1.5 7 Yes Placebo Outpatient
Llor 2012 Amoxicillin-
clavulanate
(oral)
1.5 8 Yes Placebo Outpatient
Manresa 1987 Cefaclor (oral) 1.5 8 Yes Placebo Hospital
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Table 1. Type and dose of antibiotic used (Continued)
Nouira 2001 Ofloxacin
(oral)
0.4 10 Yes Placebo Medical ICU
Petersen 1967 Chloram-
phenicol
(oral)
2 10 No Placebo Hospital
Pines 1968 Penicillin
(parenteral)
1 14 Yes Placebo Hospital
Pines 1972 Tetracycline
hydrochloride
(oral) or chlo-
ramphenicol
2 12 No Placebo Hospital
Sachs 1995 Amoxicillin
(oral)
1.5 or 1.9 7 yes Placebo Outpatient
Co-
trimoxazole
1.9
van Velzen
2017
Doxycycline
(oral)
0.1 7 Yes 30
mg oral pred-
nisolone daily
for
10 days
Placebo and 30
mg oral pred-
nisolone daily
for 10 days
Outpatient
Wang 2016 Piperacillin-
sulbactam,
ceftazidine, or
levofloxacin
Not stated As needed Yes No Placebo Hospital
IV: intravenous.
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A P P E N D I C E S
Appendix 1. Search methods used in the previous version of this review (published 2012)
Electronic searches
We identified trials using the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of
bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, CINAHL,
AMED, and PsycINFO, and handsearching of respiratory journals and meeting abstracts (see appendix for further details). All records
in the Specialised Register coded as ’COPD’ were searched using the following terms:
• antibiotic* or penicillin* or amoxycillin or ampicillin or cefalosporin* or cefaclor or cefalexine or cephalotin or cefazolin or
cefixime or cefotaxime or cefpodoxime or cephradine or ceftizoxime or ceftriaxone or cefuroxime or tetracyclin* or demeclocycline or
doxycycline or minocycline or oxytetracycline or *cycline or macrolides or azithromycin or clarithromycin or dirithromycin or
erythromycin or roxithromycin or telithromycin or troleandomycin or *thromycin or (*mycin) or fluoroquinoln* or ciprofloxacin or
gatifloxacin or gemfloxacin or grepafloxacin or levofloxacin or lomefloxacin or moxifloxacin or ofloxacin or sparfloxacin or
trovafloxacin or *floxacin or chloramphenicol or clindamycin or trimethoprim or sulfamethxazole or cotrimoxazole or carbapenem*
or meropenem or imipenem.
A search of ClinicalTrials.gov was also conducted. Databases were searched from 2005 (their inception) to April 2012. The search from
inception to 2006 is described elsewhere ( Puhan 2007). There was no restriction on the language of publication.
Searching other resources
Bibliographies of each selected RCT, as well as other systematic reviews, were scrutinised for additional potential RCTs. Authors of
identified RCTs and pharmaceutical companies producing antibiotics were contacted for other published, unpublished, or ongoing
studies.
Appendix 2. Sources and search methods for the Cochrane Airways Register of Trials
Electronic searches: core databases
Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
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Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
COPD search
1. Lung Diseases, Obstructive/
2. exp Pulmonary Disease, Chronic Obstructive/
3. emphysema$.mp.
4. (chronic$ adj3 bronchiti$).mp.
5. (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).mp.
6. COPD.mp.
7. COAD.mp.
8. COBD.mp.
9. AECB.mp.
10. or/1-9
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
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11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases
Appendix 3. Search strategy to identify relevant trials from the Cochrane Airways Trials Register
Via the Cochrane Register of Studies (CRS)
#1 MeSH DESCRIPTOR Pulmonary Disease, Chronic Obstructive Explode All
#2 MeSH DESCRIPTOR Bronchitis, Chronic
#3 (obstruct*) near3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)
#4 COPD:MISC1
#5 (COPD OR COAD OR COBD):TI,AB,KW
#6 #1 OR #2 OR #3 OR #4 OR #5
#7 antibiotic*
#8 penicillin*
#9 amoxycillin
#10 amoxicillin
#11 ampicillin
#12 cefalosporin*
#13 cefaclor
#14 cefazolin
#15 cefixime
#16 cefotaxime
#17 cefpodoxime
#18 cephradine
#19 ceftizoxime
#20 ceftriaxone
#21 cefuroxime
#22 tetracyclin*
#23 demeclocycline
#24 doxycycline
#25 minocycline
#26 oxytetracycline
#27 *cycline
#28 macrolides
#29 azithromycin
#30 clarithromycin
#31 dirithromycin
#32 erythromycin
#33 roxithromycin
#34 telithromycin
#35 troleandomycin
#36 *thromycin
#37 *mycin
#38 ciprofloxacin
#39 gatifloxacin
#40 grepafloxacin
#41 levofloxacin
#42 lomefloxacin
#43 moxifloxacin
#44 ofloxacin
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#45 sparfloxacin
#46 trovafloxacin
#47 *floxacin
#48 chloramphenicol
#49 clindamycin
#50 trimethoprim
#51 cotrimoxazole
#52 carbapenem*
#53 meropenem
#54 imipenem
#55 cefalexin*
#56 cephalothin
#57 cefalotin
#58 fluoroquinolone*
#59 gemifloxacin
#60 sulfamethoxazole
#61 cephalosporin
#62 #7 or#8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #
25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43
or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61
#63 #6 and #62
WH A T ’ S N E W
Date Event Description
29 October 2018 Amended Corrected search date.
H I S T O R Y
Review first published: Issue 12, 2012
Date Event Description
30 April 2018 New search has been performed New literature search run
30 April 2017 New citation required but conclusions have not changed Three trials added to the review. New outcome added:
time to next exacerbation. Review refreshed to reflect
up-to-date Cochrane practice, for example, background
rewritten under correct headings, summary of findings
tables added
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We added time to next exacerbation as an additional outcome.
Changes made to the protocol for the last published version of the review include the following.
• We had to change our primary outcome from treatment failure within two weeks to four weeks because reporting of the time of
the endpoint was too heterogeneous.
• Some outcomes were not reported at all (hospital admissions, admissions to an ICU).
• We did not analyse subgroups on duration of antibiotic intervention or type of antibiotic intervention because the number of
studies was too small.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Ambulatory Care; Anti-Bacterial Agents [adverse effects; ∗therapeutic use]; Disease Progression; Hospitalization; Intensive Care Units;
Pulmonary Disease, Chronic Obstructive [classification; ∗drug therapy; mortality]; Randomized Controlled Trials as Topic; Treatment
Failure
MeSH check words
Humans
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